25th International Thyroid Cancer Survivors’ Virtual Conference
September 16-18, 2022
Support • Education • Communication • Research • Hope

Sponsored by
ThyCa: Thyroid Cancer Survivors’ Association, Inc.
P.O. Box 1102, Olney, MD 20830-1102
thyca@thyca.org • (877) 588-7904
www.thyca.org
Welcome!

Dear Friends,

We are honored to welcome you to the 25th International Thyroid Cancer Survivors’ Conference. Thank you very much for coming.

These three days offer you terrific opportunities to learn and ask questions of numerous experts from a wide array of leading thyroid cancer treatment and research centers.

We invite you to also take part in the many informal roundtable discussions and the other special events during the weekend. These are great places to give and receive support from people who understand what you are going through, who want to hear your stories, and who will offer encouragement and support.

We want to express our deep appreciation to all our speakers, session leaders, and roundtable facilitators. You are donating your time because of your deep commitment to the well-being of everyone with thyroid cancer, and their families and friends. We thank you and everyone who has contributed to this weekend.

The conference is the result of more than a year of dedicated work by volunteers coast to coast. You will meet many of them here this weekend. Many others who gave long hours are unable to be here with us.

This event is also made possible through the generosity of numerous individuals and organizations who support our cause through generous financial donations as well as contributions of goods and services.

We invite you to experience all this conference has to offer. Stay in touch with each other and get information through our many free support services in the future. We look forward to getting to know you.

– The Conference Planning Team and Conference Volunteers

Table of Contents
Conference Information ...................................................3
Program Schedule - Friday ..............................................4
Program Schedule - Saturday .........................................7
Program Schedule - Sunday .........................................10
Speakers & Presenters ..................................................12
Volunteers ......................................................................18
ThyCa’s Research Funding and Grants ........................19
Medical Advisory Council ..............................................20
Our Mission – ThyCa Services, Free Tools for Education, Support, & Awareness.................................................21
Thyroid Cancer Support Groups ..................................22
In Loving Memory ..........................................................23
Executive Director and Board of Directors ....................24
Sponsors and Donors...........................................................25

Copyright © 2022 ThyCa: Thyroid Cancer Survivors’ Association, Inc.

Thank You to Our Members
No one should have to face a diagnosis of thyroid cancer alone. By joining one of our online support groups, or face-to-face support groups, you are a member of the thyroid cancer community.

We invite you to become a dues-paying member as well, and help ThyCa sustain, strengthen, and extend our services and support to survivors, families, and friends around the world, as well as contribute to our research grants.

Your support also makes possible our outreach and awareness campaigns to the public.

• We have members with each type of thyroid cancer— papillary, follicular, medullary, anaplastic, and variants.
• Our members range in age from teens to 80s.
• Our members also include caregivers, health care professionals, and friends supporting our mission.
• Members live in 42 states and the District of Columbia, two Canadian provinces, and numerous other countries.
• We welcome new members at any time.
• Members may join for 1 year, 2 years, or as Lifetime Members.
• Membership forms are available at the online or mail-in on our website’s Membership page.
• Thank you very much for your wonderful support!
**Conference Information**

**REGISTRATION - CONFERENCE CENTRAL**
www.thyca.org/conference

**ThyCa INFORMATION TABLES**
Visit our website at www.thyca.org for thyroid cancer publications, plus information about ThyCa local support groups, online groups, the Person-to-Person Network, volunteer opportunities, ThyCa Membership, and the ThyCa Rally for Research and Research Grants.

**QUESTIONS and SUGGESTIONS**
If you have questions about the Program or ThyCa, please email conference@thyca.org.

**FUNDRAISER AUCTION**
Numerous exciting auction items have been donated. Proceeds will benefit ThyCa's Research Funds and Grants for Thyroid Cancer Research. Help us reach our goal of a future without thyroid cancer!

**ThyCa AWARENESS and SPIRIT ITEMS**
We have Thyroid Cancer Awareness and Spirit items for sale in our Exhibit Hall Booth – wristbands, pins, ribbon magnets, shirts, note cards, bracelets, and more with the ThyCa logo. Proceeds from these unique items benefit our free support services, outreach, and research funding.

**PLEASE TAKE NOTE**
- ThyCa: Thyroid Cancer Survivors’ Association, Inc., is not necessarily in agreement with or responsible for the statements made by any of the presenters at this conference. The speakers will reflect a variety of perspectives.
- Circumstances may require the cancellation of a session, the substitution of a presenter, or a change in a session time.
- Respect Privacy. People are sharing their personal experiences and sensitive information, and we can all benefit from this. Feel free to take notes for your personal use, but please respect people’s privacy. What’s said in the room stays in the room.
- No Solicitations. Please, no solicitations, promotions, recruiting, direct or indirect marketing, fundraising for other organizations, or distribution of materials for yourself, your projects or services, your organization, or other organizations’ or individuals’ services, projects, fundraisers, or products, whether nonprofit or for-profit. This conference is a nonprofit thyroid cancer support and education event sponsored by ThyCa and run by dozens of volunteers. We want to keep our focus on learning, sharing our experiences, hearing others' experiences, and supporting each other.

Visit ThyCa’s Information Tables
Talk with our volunteers to learn about...
- Local support groups coast to coast in the U.S. Honduras, and Ireland
- One-to-one support from a ThyCa volunteer, matched by type of thyroid cancer, through our Person-to-Person Network
- FREE downloadable Low-Iodine Cookbook, 9th Edition
- FREE downloadable handbooks: Thyroid Cancer Basics, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, and Thyroid Nodules: Testing and Follow-Up
- Thyroid Cancer Awareness Month
- Volunteer opportunities
- ThyCa membership form

Shop for ThyCa Spirit Items at https://thyca.org/how-to-help/spirit_items/
• All program times are EDT (New York City time)
• Check out our online auction, https://bit.ly/ThyCaAuction2022
• Your feedback is important! Please fill out the session evaluation survey at the end of each session.

<table>
<thead>
<tr>
<th>Session Key by Suggested Audience</th>
</tr>
</thead>
<tbody>
<tr>
<td>You are welcome to attend any session. The key indicates sessions of interest to a particular audience.</td>
</tr>
<tr>
<td><strong>A:</strong> Anaplastic</td>
</tr>
<tr>
<td><strong>AYA:</strong> Adolescent/Young Adult</td>
</tr>
<tr>
<td><strong>N:</strong> Newly Diagnosed</td>
</tr>
<tr>
<td><strong>H:</strong> Hurthle Cell</td>
</tr>
<tr>
<td><strong>M:</strong> Medullary</td>
</tr>
<tr>
<td><strong>PF:</strong> Papillary/Follicular</td>
</tr>
<tr>
<td><strong>SR:</strong> Session to be Recorded</td>
</tr>
<tr>
<td><strong>ADV:</strong> Advanced Disease</td>
</tr>
<tr>
<td><strong>ALL:</strong> All Attendees</td>
</tr>
</tbody>
</table>

---

**FRIDAY, SEPTEMBER 16, 2022 | All times listed as Eastern Daylight Time**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 8:00 – 9:00 a.m. | 001  | **Open house: Navigating through the conference. Things to know and questions to ask.**  
Daria Jerauld, ThyCa Volunteer  
**ALL,SR** |
| 9:30 – 10:30 a.m. | 101  | **Roundtable: If you’re new to thyroid cancer – things to know and questions to ask.**  
Barb Allhoff, ThyCa Volunteer  
**N** |
| 102  | **Roundtable: If this is your first conference – things to know and questions to ask.**  
Abby Melendez, ThyCa Volunteer  
**ALL** |
| 103  | **Get “schooled”: Educational accommodations and advocacy for children diagnosed with thyroid cancer.**  
Pam Mendenhall, LISW, ThyCa Pediatric Support Moderator  
**PED,SR** |
| 104  | **Update on the management of anaplastic thyroid cancer**  
Maria E. Cabanillas, MD, Oncologic Endocrinologist  
**A,SR** |
| 105  | **Caregivers roundtable**  
Miguel Melendez, ThyCa Volunteer  
**ALL** |
| 10:40 – 10:50 a.m. | 116  | **Welcome and announcements**  
Gary Bloom, ThyCa Executive Director and Howard Solomon, ThyCa Board Chair  
**ALL** |
| 11:00 a.m. – 12:30 p.m. | 121  | **Getting to know each other: Open-microphone roundtables**  
ThyCa Volunteers  
**ALL** |
| 122  | **Poorly differentiated thyroid cancer roundtable: Getting to know each other**  
Julie Martwick, ThyCa Volunteer  
**ADV,PF** |
| 123  | **Medullary thyroid cancer roundtable: Getting to know each other**  
Bill McClain and Kelley Pratt, ThyCa Volunteers  
**M** |
| 124  | **Anaplastic thyroid cancer roundtable: Getting to know each other**  
Cheri Lindle and Patti Turner, ThyCa Volunteers  
**A** |
<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>131</td>
<td>1:00 – 2:00 p.m.</td>
<td>Improving thyroid cancer patient outcomes, experience, and treatment decision-making</td>
<td>Susan Pitt, MD, MPH, Endocrine Surgeon</td>
</tr>
<tr>
<td>132</td>
<td>1:00 – 2:00 p.m.</td>
<td>Contemporary surgical treatment of differentiated (papillary and follicular) thyroid cancer and recurrent thyroid cancer</td>
<td>R. Alex Harbison, MD, MS, Endocrine Surgeon</td>
</tr>
<tr>
<td>133</td>
<td>1:00 – 2:00 p.m.</td>
<td>CAR T-cell therapy for medullary thyroid cancer: The personal story that inspired the science</td>
<td>Roger B. Cohen, MD, Medical Oncologist; Donald L. Siegel, PhD, MD, Transfusion Medicine; and Kelley Pratt, ThyCa Volunteer</td>
</tr>
<tr>
<td>134</td>
<td>1:00 – 2:00 p.m.</td>
<td>Adjusting to and coping with thyroid cancer: What does this mean and look like for me?</td>
<td>Kimberly M. Davis, PhD, Clinical Psychologist</td>
</tr>
<tr>
<td>135</td>
<td>1:00 – 2:00 p.m.</td>
<td>MTC and MEN2A/B: implications for the patient and their family</td>
<td>Ruth T. Casey, MD, Endocrinologist, Tom R. Kurzawinski, MD, Endocrine Surgeon, and Jo Grey, CEO of AMEND</td>
</tr>
<tr>
<td>141</td>
<td>2:30 – 3:30 p.m.</td>
<td>Your mouth, salivary glands, and teeth: Preventing and solving issues caused by treatments, including radioactive iodine or external beam radiation.</td>
<td>Mark S Chambers, DMD, MS, Oral Medicine Specialist</td>
</tr>
<tr>
<td>142</td>
<td>2:30 – 3:30 p.m.</td>
<td>Overview and discussion about thyroid cancer and pregnancy</td>
<td>Kaniksha Desai, MD, ECNU, Endocrinologist; and Caroline T. Nguyen, MD, Endocrinologist</td>
</tr>
<tr>
<td>143</td>
<td>2:30 – 3:30 p.m.</td>
<td>Medullary thyroid cancer: What is it, and what do I do now? Understand the terms, and learn how to navigate treatment at the beginning of the journey.</td>
<td>Mimi I. Hu, MD, Endocrinologist</td>
</tr>
<tr>
<td>144</td>
<td>2:30 – 3:30 p.m.</td>
<td>How does thyroid cancer differ when it’s in children and teenagers, compared to adults?</td>
<td>Jonathan Wasserman, MD, PhD, Pediatric Endocrinologist</td>
</tr>
<tr>
<td>145</td>
<td>2:30 – 3:30 p.m.</td>
<td>Development of a Decision Aid for Decisions about Radioactive Iodine Therapy among Patients Diagnosed with Thyroid Cancer</td>
<td>Alaina Carr, PhD, Clinical Psychologist</td>
</tr>
<tr>
<td>151</td>
<td>4:00 – 5:00 p.m.</td>
<td>Approaches for RAI therapy and RAI refractory (non-avid, RAI resistant) disease</td>
<td>Mabel Ryder, MD, Endocrinologist</td>
</tr>
<tr>
<td>152</td>
<td>4:00 – 5:00 p.m.</td>
<td>Patient advocacy issues in the era of pandemic and digital health</td>
<td>Erik Blomain, MD, PhD, Radiation Oncologist and Patient Advocate</td>
</tr>
<tr>
<td>153</td>
<td>4:00 – 5:00 p.m.</td>
<td>Ask a doctor your questions about medullary thyroid cancer</td>
<td>Mimi I. Hu, MD, Endocrinologist</td>
</tr>
<tr>
<td>154</td>
<td>4:00 – 5:00 p.m.</td>
<td>The ABCs of papillary and follicular thyroid cancer and variants: Understanding key terms, concepts, and initial diagnostic and treatment steps</td>
<td>Kaniksha Desai, MD, ECNU, Endocrinologist</td>
</tr>
<tr>
<td>155</td>
<td>4:00 – 5:00 p.m.</td>
<td>Regulating our Dysregulation: A guided relaxation session followed by a discussion offering practical tools for enhancing our quality of life</td>
<td>Donna Sherman, MSW, LCSW, Behavioral Health Coach</td>
</tr>
</tbody>
</table>
FRIDAY, SEPTEMBER 16, 2022 continued | All times listed as Eastern Daylight Time

5:30 – 6:30 p.m.

161

**Roundtable: Connecting with community through storytelling**

Participants will explore how storytelling can help us process difficult experiences and how sharing our stories can help increase our sense of connection. Participants will create their own story timelines in this session and will share a part of their story (if comfortable) with a partner during the session. In closing, participants will identify how they want to write the next chapter of their narrative.

Jessie Larson-Wu, MA, LPC, Mental Health Therapist, ThyCa’s Director of Podcasts

162

**The risks of secondary cancers from radioactive iodine treatment**

Erik Blomain, MD, PhD, Radiation Oncologist & Patient Advocate

ADV, AYA, H, N, PED, PF, SR

163

**Medullary thyroid cancer in 2022: Considerations before, during, and after surgery**

Mark E. Zafereo, MD, Head and Neck Surgeon

M, SR

164

**Roundtable: Learn how ThyCa serves the thyroid cancer community through Social Media and how you can be a micro-influencer**

Daria Jerauld, ThyCa Director of Social Media

ALL

165

**Protecting yourself and your family by planning ahead**

Estate planning can be overwhelming and can often bring up topics that are difficult to discuss. However, being prepared can also bring a sense of comfort. This seminar will cover the various documents that can make up an estate plan, things to consider as you begin the process of creating your plan and options available to individuals to protect their medical decision-making rights.

Monica Fawzy Bryant, Esq, Attorney

7:00 – 8:30 p.m.

171

**Young adults virtual meet-up**

For people ages 15 to 39.

Anjali Kapoor-Davis, ThyCa Volunteer

AYA

172

**Virtual anaplastic thyroid cancer meet-up**

Cheri Lindle and Patti Turner, ThyCa Volunteers

A

173

**“Meddie” (medullary thyroid cancer) virtual meet-up**

Bill McClain, ThyCa Volunteer

M

174

**Virtual papillary and follicular thyroid cancer meet-up**

Theresa Wickerham, ThyCa Program Coordinator

ADV, H, N, PED, PF

7:30 – 8:30 p.m.

185

**Thyroid cancer trials 2022, a presentation from Australia**

Bruce Robinson, MD, Endocrinologist

ADV, AYA, H, M, PED, PF, SR

RECORDED SESSIONS for on-demand listening [languages noted]

(More sessions may be added to this section as they become available)

500

**Challenges and difficulties in pathological diagnosis of thyroid cancer. [English]**

Shoko Kure, MD, PhD, Pathologist

ALL

511

**Diagnóstico e manejo do cancer de tireoide medular. [Português]**

Ana O. Hoff, MD, Endocrinologista

M

521

**甲状腺结节：常识介绍。 [简体中文]**

关海霞, 医学博士, 内分泌科医生。

[全部]

522

**甲状腺癌的诊断。 [简体中文]**

王卓颖, 医学博士, 头颈外科医生。

[全部]

523

**甲状腺癌的治疗。 [简体中文]**

王卓越, 医学博士, 头颈外科医生。

[全部]
**Session Key by Suggested Audience**

You are welcome to attend any session. The key indicates sessions of interest to a particular audience.

- **A**: Anaplastic
- **AYA**: Adolescent/Young Adult
- **H**: Hurthle Cell
- **M**: Medullary
- **N**: Newly Diagnosed
- **PED**: Pediatric
- **PF**: Papillary/Follicular
- **SR**: Session to be Recorded

---

**8:30 – 9:30 a.m.**

<table>
<thead>
<tr>
<th>201</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discussion about thyroid nodules and pathological diagnosis, and types of thyroid tumors and pathological features</td>
</tr>
<tr>
<td>Zubair W. Baloch, MD, PhD, Pathologist</td>
</tr>
<tr>
<td><strong>ADV, AYA, H, PED, PF, SR</strong></td>
</tr>
</tbody>
</table>

**Helping families communicate better with each other and with their medical team, including the value of emotional intelligence and the role of behavioral styles**

Cheri Lindle, MEd, ThyCa Volunteer

**All, SR**

---

**202**

Ask a doctor your questions about papillary, follicular and Hurthle Cell thyroid cancers and variants

Valentina D. Tarasova, MD, Endocrinologist

**ADV, AYA, H, N, PED, PF, SR**

---

**203**

Roundtable: Discussion for radioactive iodine resistant thyroid cancer survivors. How do we manage our care?

Anjali Kapoor-Davis and Abby Melendez, ThyCa Volunteers

**ADV, H, PF**

---

**204**

Voice issues roundtable: Share your tips and tricks for coping with voice issues

Daria Jerauld and Anjali Kapoor-Davis, ThyCa Volunteers

**All**

---

**10:00 – 11:00 a.m.**

<table>
<thead>
<tr>
<th>201</th>
</tr>
</thead>
<tbody>
<tr>
<td>Am I a candidate for a non-surgical treatment option? A discussion about percutaneous alcohol ablation, and radiofrequency ablation</td>
</tr>
<tr>
<td>Shahzad Ahmad, MD, FACE, ECNU, Endocrinologist; Jules Aljammal, MD, ECNU, Endocrinologist; and Iftikhar A Malik MD, ECNU, FACE, Endocrinologist</td>
</tr>
<tr>
<td><strong>ADV, AYA, H, M, N, PF, SR</strong></td>
</tr>
</tbody>
</table>

Moderator: Jennifer L. Holkem, Executive Director, Save Your Thyroid.

---

<table>
<thead>
<tr>
<th>204</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haga sus preguntas a el médico en español</td>
</tr>
<tr>
<td>Carlos S. Duque, MD, Cirujano de Cabeza y Cuello; y Danica M. Vodopivec, MD, Endocrinólogo Oncológico</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>205</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and announcements</td>
</tr>
<tr>
<td>Gary Bloom, ThyCa Executive Director and Howard Solomon, ThyCa Board Member</td>
</tr>
</tbody>
</table>

**All**

---

<table>
<thead>
<tr>
<th>206</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discuss the treatment of medullary thyroid cancer</td>
</tr>
<tr>
<td>Jo Gorringe and Bill McClain, and Kathryn Wall, ThyCa Volunteers</td>
</tr>
<tr>
<td><strong>M</strong></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>207</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discuss the treatment of medullary thyroid cancer</td>
</tr>
<tr>
<td>Jochen J. Lorch, MD, MSc, Medical Oncologist</td>
</tr>
<tr>
<td><strong>A, ADV, H, SR</strong></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>208</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discuss the treatment of medullary thyroid cancer</td>
</tr>
<tr>
<td>Carlos S. Duque, MD, Cirujano de Cabeza y Cuello; y Danica M. Vodopivec, MD, Endocrinólogo Oncológico</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>209</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discussion about thyroid nodules and pathological diagnosis, and types of thyroid tumors and pathological features</td>
</tr>
<tr>
<td>Zubair W. Baloch, MD, PhD, Pathologist</td>
</tr>
<tr>
<td><strong>ADV, AYA, H, PED, PF, SR</strong></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>210</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ask a doctor your questions about papillary, follicular and Hurthle Cell thyroid cancers and variants</td>
</tr>
<tr>
<td>Valentina D. Tarasova, MD, Endocrinologist</td>
</tr>
<tr>
<td><strong>ADV, AYA, H, N, PED, PF, SR</strong></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>211</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roundtable: Discussion for radioactive iodine resistant thyroid cancer survivors. How do we manage our care?</td>
</tr>
<tr>
<td>Anjali Kapoor-Davis and Abby Melendez, ThyCa Volunteers</td>
</tr>
<tr>
<td><strong>ADV, H, PF</strong></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>212</th>
</tr>
</thead>
<tbody>
<tr>
<td>Voice issues roundtable: Share your tips and tricks for coping with voice issues</td>
</tr>
<tr>
<td>Daria Jerauld and Anjali Kapoor-Davis, ThyCa Volunteers</td>
</tr>
<tr>
<td><strong>All</strong></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>213</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medullary thyroid cancer roundtable: Answering any questions you have so far</td>
</tr>
<tr>
<td>Jo Gorringe and Bill McClain, and Kathryn Wall, ThyCa Volunteers</td>
</tr>
<tr>
<td><strong>M</strong></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>214</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discussion with a doctor about anaplastic thyroid cancer and Hurthle cell thyroid cancer. What’s new?</td>
</tr>
<tr>
<td>Jochen J. Lorch, MD, MSc, Medical Oncologist</td>
</tr>
<tr>
<td><strong>A, ADV, H, SR</strong></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>215</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haga sus preguntas a el médico en español</td>
</tr>
<tr>
<td>Carlos S. Duque, MD, Cirujano de Cabeza y Cuello; y Danica M. Vodopivec, MD, Endocrinólogo Oncológico</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>216</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and announcements</td>
</tr>
<tr>
<td>Gary Bloom, ThyCa Executive Director and Howard Solomon, ThyCa Board Member</td>
</tr>
<tr>
<td><strong>All</strong></td>
</tr>
</tbody>
</table>

---

**Session Key by Suggested Audience**

You are welcome to attend any session. The key indicates sessions of interest to a particular audience.

- **A**: Anaplastic
- **AYA**: Adolescent/Young Adult
- **H**: Hurthle Cell
- **M**: Medullary
- **N**: Newly Diagnosed
- **PED**: Pediatric
- **PF**: Papillary/Follicular
- **SR**: Session to be Recorded
### 11:30 a.m. – 12:30 p.m.

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>231</td>
<td>Patient decision-making in low-risk papillary thyroid cancer, including active surveillance</td>
<td>Louise Davies, MD, MS, FACS, Otolaryngologist; Anna Sawka, MD, PhD, Endocrinologist; and R. Michael Tuttle, MD, Endocrinologist</td>
</tr>
<tr>
<td>232</td>
<td>Test your cancer: Genomic cancer testing overview</td>
<td>Valerie Bastani, BSN, RN, OCN; Shari Bates, BSN, RN, OCN, CCM; and Valentina D. Tarasova, MD, Endocrinologist</td>
</tr>
<tr>
<td>233</td>
<td>Medullary thyroid cancer: Locating disease and treatment options for metastases using lab results and imaging</td>
<td>Douglas W. Ball, MD, Endocrinologist</td>
</tr>
</tbody>
</table>

### 1:00 – 2:00 p.m.

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>234</td>
<td>Pediatric thyroid cancer roundtable: Coping, treatment options, and being part of a community of survivors</td>
<td>Carol DiFelice and Pam Mendenhall, ThyCa Volunteers</td>
</tr>
<tr>
<td>235</td>
<td>Haga sus preguntas a el médico en español</td>
<td>Carlos S. Duque, MD, Cirujano de Cabeza y Cuello; and Danica M. Vodopivec, MD, Endocrinólogo Oncológico</td>
</tr>
<tr>
<td>236</td>
<td>Discussion about the low-iodine diet</td>
<td>Daria Jerauld and Becky Johnson, ThyCa Volunteers</td>
</tr>
<tr>
<td>237</td>
<td>I’ve had surgery followed by radioactive iodine. Now I have non-avid (RAI resistant) disease. When should I consider biomarker testing to look for NTRK, RET and other therapeutic targets?</td>
<td>Naifa L. Busaidy, MD, Endocrinologist</td>
</tr>
<tr>
<td>238</td>
<td>Ask a doctor your questions about medullary thyroid cancer</td>
<td>Douglas W. Ball, MD, Endocrinologist</td>
</tr>
<tr>
<td>239</td>
<td>Living with hypoparathyroidism which sometimes is a side effect of thyroid cancer treatment</td>
<td>Michael A. Levine, MD, MACE, FAAP, FACP, Pediatric Endocrinologist</td>
</tr>
<tr>
<td>240</td>
<td>Roundtable: How do I meditate anyway? Using mindful meditation for stress relief</td>
<td>Roberta Perry, ThyCa Volunteer</td>
</tr>
<tr>
<td>241</td>
<td>The extent of surgical treatment for differentiated thyroid cancer: Shared decision making with your surgeon</td>
<td>Amanda M. Laird, MD, Endocrine Surgeon; and Lilah F. Morris, MD, FACS, Endocrine Surgeon</td>
</tr>
</tbody>
</table>

### 2:30 – 3:30 p.m.

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>242</td>
<td>Targeted therapies (i.e.: multi-kinase inhibitors, RET and NTRK inhibitors) in advanced thyroid cancer</td>
<td>Jonathan Wadsley, MA, MRCP, FRCR, Oncologist</td>
</tr>
<tr>
<td>243</td>
<td>Do I have the right medical team for my situation? Should I consider getting a second opinion? Do I need an oncologist for my care?</td>
<td>Naifa L. Busaidy, MD, Endocrinologist</td>
</tr>
<tr>
<td>244</td>
<td>The use of Thyrogen® versus T4 withdrawal to prepare for radioactive iodine treatment or scans and/or for stimulated thyroglobulin testing, with or without scans</td>
<td>Sarimar N. Agosto Salgado, MD, Oncologic Endocrinologist</td>
</tr>
<tr>
<td>245</td>
<td>Medullary thyroid cancer roundtable: Breakout rooms by disease status to talk after hearing from some of the doctors</td>
<td>Bill Nelson and Kelley Pratt, ThyCa Volunteers</td>
</tr>
</tbody>
</table>
4:00 – 5:00 p.m.

Panel discussion: Understanding thyroid hormone replacement therapy
Francesco S. Celi, MD, Endocrinologist; Jacqueline Jonklaas, MD, PhD, MPH, Endocrinologist; and Lizzy McAninch, MD, Endocrinologist

Designing clinical trials for precision oncology
Vivek Subbiah, MD, Clinical Trialist

Nutrition roundtable: Ask a nutritionist your questions about healthy eating
Catalina Ovalle, BSND, Nutritionist

264
Thyroid Cancer and the Importance of Your Story
Filmmaker and thyroid cancer survivor, Bryn Silverman, will walk participants through her creative process and what she’s learned as a patient in the making of her documentary film about her treatment. Participants will be invited to share their own experiences and thoughts on the subject. What is your story? How have you maintained/discovered/rewritten your own personal narrative since your diagnosis?
Naveen Chaubal, Producer; Kate Mitchell, MD; and Bryn Silverman, Filmmaker and Thyroid Cancer Survivor

265
Roundtable: Discussion among adolescents and young adults. For people ages 15 to 39.
Anjali Kapoor-Davis, ThyCa Volunteer

266
A discussion on radioactive iodine therapy: when to use it, how much to use and radiation safety precautions after therapy
Jennifer Kwak, MD, Nuclear Medicine Physician

5:30 – 6:30 p.m.

Panel discussion: Question and answer session. We will address whatever questions have come up as the meeting has progressed.
Moderator: R. Michael Tuttle, MD, Endocrinologist.
Panelists: Sarimar N. Agosto Salgado, MD, Oncologic Endocrinologist; Jennifer Choe, MD, PhD, Medical Oncologist; and Avital Harari, MD, MSc, Endocrine Surgeon

Music therapy and how it relates to supporting all that goes into a cancer diagnosis and journey
Sharon Hickox, MM, LPMT, MT-BC, CCTSI, Music Therapist

AYA roundtable: Self-care and thyroid cancer. For people ages 15 to 39
Bev McLaughlin, MA, Patient Navigator

Roundtable: Anaplastic thyroid cancer
Cheri Lindle and Patti Turner, ThyCa Volunteers

275
Living your best life: How palliative care can improve your quality of life
Having a difficult illness can affect your life in many ways. Join us for this session to find out what you can do to manage the impact your illness has on your life. At this event, we will share ways to live your best life using a holistic, person-centered approach. We will talk about physical symptoms as well as emotional and spiritual well-being. You’ll also learn about the medical specialty, called palliative care, and how it can give you an extra level of support and improve your quality of life.
Grant M. Smith, MD, Palliative Care Physician

Support the 21st ThyCa Auction
Go to https://bit.ly/ThyCaAuction2022 and help us raise much-needed funds for thyroid cancer research. The auction ends at 9 p.m. EDT tonight.
- All program times are EDT (New York City time)
- Your feedback is important! Please fill out the session evaluation survey at the end of each session.

<table>
<thead>
<tr>
<th>Session Key by Suggested Audience</th>
</tr>
</thead>
<tbody>
<tr>
<td>You are welcome to attend any session. The key indicates sessions of interest to a particular audience.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>A: Anaplastic</th>
<th>ADV: Advanced Disease</th>
<th>ALL: All Attendees</th>
</tr>
</thead>
<tbody>
<tr>
<td>AYA: Adolescent/Young Adult</td>
<td>H: Hurthle Cell</td>
<td>M: Medullary</td>
</tr>
<tr>
<td>N: Newly Diagnosed</td>
<td>PED: Pediatric</td>
<td></td>
</tr>
<tr>
<td>PF: Papillary/Follicular</td>
<td>SR: Session to be Recorded</td>
<td></td>
</tr>
</tbody>
</table>

### 10:00 – 11:00 a.m.

<table>
<thead>
<tr>
<th>301</th>
<th>Complications from treatments and balancing benefits-risks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Megan R. Haymart, MD, Endocrinologist</td>
</tr>
<tr>
<td></td>
<td><strong>ADV,H,PF,SR</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>302</th>
<th>Recurrent thyroid cancer: screening and treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cord Sturgeon, MD, MS, Endocrine Surgeon</td>
</tr>
<tr>
<td></td>
<td><strong>ADV,AYA,H,PED,PF,SR</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>303</th>
<th>Thyroid cancer roundtable: A discussion on fitness and exercise and positive mental attitude</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bill Nelson, Jr., ThyCa Volunteer</td>
</tr>
<tr>
<td></td>
<td><strong>ALL</strong></td>
</tr>
</tbody>
</table>

### 11:10 – 11:20 a.m.

<table>
<thead>
<tr>
<th>304</th>
<th>ThyCa support group facilitators: current and prospective</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Abby Melendez, Director of Support Groups and Theresa Wickerham, ThyCa Program Coordinator</td>
</tr>
<tr>
<td></td>
<td><strong>ALL</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>305</th>
<th>Immunotherapy and thyroid cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ann W. Gramza, MD, Medical Oncologist</td>
</tr>
<tr>
<td></td>
<td><strong>ALL,SR</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>306</th>
<th>Pediatric thyroid cancer roundtable: A parent’s story about NTRK and discussing the importance of tumor testing as well as the latest updates</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Andrew J. Bauer, MD, FAAP, Pediatric Endocrinologist; Theodore W. Laetsch, MD, Pediatric Oncologist; Kristine Frischhertz and Susan Spinosa, ThyCa Volunteers</td>
</tr>
<tr>
<td></td>
<td><strong>PED,SR</strong></td>
</tr>
</tbody>
</table>

### 11:30 a.m. – 12:30 p.m.

<table>
<thead>
<tr>
<th>316</th>
<th>Welcome and announcements</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gary Bloom, ThyCa Executive Director and Howard Solomon, ThyCa Board Chair</td>
</tr>
<tr>
<td></td>
<td><strong>ALL</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>321</th>
<th>A preview of preliminary work done for the next iteration of the American Thyroid Association guidelines for differentiated thyroid cancer (papillary or follicular thyroid cancer).</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Julie Ann Sosa, MD, MA, Surgeon</td>
</tr>
<tr>
<td></td>
<td><strong>N,PF,SR</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>322</th>
<th>Hurthle cell thyroid cancers – these are NOT papillary or follicular thyroid cancers. Where is the research going in this disease and what has been done so far?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>David G. McFadden, MD, Endocrinologist</td>
</tr>
<tr>
<td></td>
<td><strong>ADV,AYA,H,SR</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>323</th>
<th>Medullary thyroid cancer: Medical management of a chronic disease</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Danica M. Vodopivec, MD, Oncologic Endocrinologist</td>
</tr>
<tr>
<td></td>
<td><strong>M,SR</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>325</th>
<th>Roundtable: Conquer the fear of cancer recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Theresa Wickerham, ThyCa Program Coordinator</td>
</tr>
<tr>
<td></td>
<td><strong>ADV,AYA,H,PF</strong></td>
</tr>
</tbody>
</table>
1:00 – 2:00 p.m.

331 Surgical complications: Voice issues and other problems
David Myssiorek, MD, FACS, Otolaryngologist

332 Systemic treatment options for radioactive iodine-refractory metastatic papillary, follicular, and hurthle cell thyroid cancer
Vineeth K. Sukrithan, MD, Medical Oncologist

333 Medullary thyroid cancer roundtable: Wrapping up the conference. Does anyone have any more questions?
Karen Geisenberger and Jo Gorringe, ThyCa Volunteers

2:30 – 3:30 p.m.

334 Pediatric thyroid cancer. Ask a doctor your questions about pediatric thyroid cancer, from minimally invasive to advanced disease
Andrew J. Bauer, MD, FAAP, Pediatric Endocrinologist

335 Roundtable: AYA thyroid cancer and a discussion on friendships, dating, relationships, and how thyroid cancer affects them. For people ages 15 to 39
Anjali Kapoor-Davis, ThyCa Volunteer

3:35 – 4:00 p.m.

336 Haga sus preguntas a la médica en español
Amanda LaGreca, MD, Endocrinólogo

341 The importance of lifetime follow-up
Amanda LaGreca, MD, Endocrinologist

342 Poorly differentiated thyroid cancer roundtable: What have we learned this weekend
Julie Martwick, ThyCa Volunteer

343 Precision medicine: Integrating computational analysis with clinical and genomic information to inform clinical decision-making to offer better care for thyroid cancer patients
Theodora Pappa, MD, PhD, Endocrinologist

344 Nonsurgical treatment options for primary PTC: Patients share their experience with radiofrequency ablation
Ralph P. Tufano, MD, MBA, FACS, Otolaryngologist; and Jennifer L. Holkem, Executive Director, Save Your Thyroid

345 Thriving through Connection: the importance of nurturing mental health during the thyroid cancer journey.
It might be helpful to have paper and writing/drawing utensil available for this session
Laura Slagle, MA, LMFT, Licensed Marriage and Family Therapist

356 Conference wrap-up: Resources and next steps after the conference, your feedback on the conference, and suggestions for next year.
Gary Bloom, ThyCa Executive Director and Theresa Wickerham, ThyCa Program Coordinator

Thank you for attending!
We hope to see you in person next year!
Sarimar N. Agosto Salgado, MD is an oncologic endocrinologist at Moffitt Cancer Center in Tampa, Florida. Dr. Agosto Salgado’s clinical interest centers on the management of thyroid nodules and all stages and types of thyroid cancer, including administration of systemic therapies for aggressive tumors. She is also interested in the management of hereditary endocrine neoplasia disorders, pituitary tumors, adrenal tumors, adrenocortical carcinoma and pheochromocytoma-paraganglioma tumors. Her research interest focuses on intermediate-high risk thyroid cancers in terms of management, surveillance protocols, targeted therapies and potential redifferentiation of tumors resistant to radioactive iodine.

Shahzad Ahmad, MD is an endocrinologist at The Thyroid Clinic in Salt Lake City, Utah. Dr. Ahmad has performed more radiofrequency ablation (RFA) procedures than any endocrinologist in the US. He performed the first successful RFA procedure of a parathyroid tumor and the first RFA of a medullary thyroid cancer recurrence in North America. Dr. Ahmad also has performed the first RFA procedure on a toxic thyroid nodule (hyperfunctioning) in the US. Dr. Ahmad completed his residency in Internal Medicine at Mount Sinai School of Medicine in New York, New Jersey and then went on to an Endocrine fellowship at UCLA Harbour. He was also an Assistant Professor at the University of San Francisco School of Medicine. His primary focus is the diagnosis, and medical treatment of thyroid dysfunction, nodules, and cancer. Dr. Ahmad is ECNU certified, a professional certification awarded to Endocrinologists who have expertise in thyroid ultrasounds, and procedures. Dr. Ahmad has been involved in trying to bring RFA to the USA for over 4 years and has extensively practiced this technique on tissue models. He has now successfully ablated over 150 nodules/Goiters without complications.

Jules Aljammal, MD, ECNU is an endocrinologist at The Thyroid Clinic in Salt Lake City, Utah. Dr. Aljammal completed his fellowship in endocrinology at the University Of Pittsburgh Medical Center in 2014. Thereafter, he started his own medical practice in Salt Lake City, Utah, which is completely focused on the management of thyroid and parathyroid disorders. He has extensive experience in performing RFA, which he first brought to Salt Lake City in 2018. Since that time, he has performed more than 300 cases and has published his work in “Journal of the Endocrine Society”. His most recent paper on thermal ablation is the first to be published in the United States by an endocrinologist. Lastly, to promote interest and advance the field of interventional endocrinology, he created the North American Society of Interventional Endocrinologist and currently serves as its first President.

Douglas W. Ball, MD is an endocrinologist at Johns Hopkins Medicine in Baltimore, Maryland. Dr. Ball is an associate professor of medicine specializing in Thyroid Cancer, Medullary Thyroid Cancer, and Multiple Endocrine Neoplasia. His laboratory studies mechanisms underlying the neuroendocrine phenotype seen in some human cancers. Dr. Ball is active in developing new therapies for medullary thyroid cancer, and works in this translational research program in collaboration with other researchers and clinicians. Dr. Ball graduated from George Washington University Medical School and completed further training in Internal Medicine and in Endocrinology and Metabolism at the University of Pittsburgh and Johns Hopkins University. He is the author of numerous peer-reviewed medical journal articles and has been a speaker at previous ThyCa educational events. He is a ThyCa medical advisor.

Zubair W. Baloch, MD, PhD is professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania. He earned his medical degree from Liaquat Medical College in Jamshoro, Pakistan and his PhD from Hahnemann University in Philadelphia. Dr. Baloch’s research expertise is in molecular and immunopathology of thyroid neoplasia and is clinical expertise is in endocrine pathology (cytology and histopathology).

Valerie Bastani, BSN, RN, OCN is an oncology nurse educator on the Precision Medicine Team at Bayer HealthCare Pharmaceuticals. She has been an active member of the Oncology Nursing Society (ONS) since 1996 and has held several board positions within her local chapter. Valerie earned the Oncology Nursing accreditation in 2004 and maintained certification throughout her nursing career. She received her Bachelor of Science in Nursing from Florida State University. She is responsible for educating clinical staff about adverse event management and oncology disease states. Valerie gained most of her clinical experience as a Clinical Nurse Manger, spending over 15 years at 2 large oncology practices in Orlando, Florida. She was also on the Florida Hospital IV Specialty Team as a Venous Access Specialist. Valerie is passionate about education and patient advocacy.

Shari Bates, BSN, RN, OCN, CCM is an oncology nurse educator on the precision medicine team at Bayer HealthCare Pharmaceuticals based out of the state of Washington. Prior to transitioning to a nurse educator role in 2017, she held the position of Oncology Nurse Navigator at UW Medicine Valley Medical Center in Renton, Washington. Her clinical background encompasses experience in neuro-oncology, community practice, and specialty case management. She holds certifications in Oncology Nursing, Case Management, and Care Coordination and Transition Management.

Andrew J. Bauer, MD, FAAP is a pediatric endocrinologist and the director of the Thyroid Center at The Children’s Hospital of Philadelphia in Pennsylvania. Dr. Bauer retired from the United States Army after 29 years of service, to include two combat tours in Iraq. His clinical and research interests are focused on the study of pediatric thyroid disorders, including hyperthyroidism, hypothyroidism, thyroid nodular disease, thyroid cancer, and familial thyroid tumor syndromes. Dr. Bauer serves as co-chair of the American Thyroid Association’s (ATA) Pediatric Thyroid Cancer Guidelines and as a member of the ATA’s board of directors. In 2018, Dr. Bauer served on the World Health Organization, International Agency for Research on Cancer expert group that published guidelines on thyroid screening after nuclear disasters. He has spoken at many ThyCa events. Dr. Bauer is a ThyCa medical advisor.

Erik Blomain, MD, PhD is a radiation oncologist at Stanford University in California. Dr. Blomain earned his undergraduate degrees at Cornell University majoring in both Biology and Classic Civilizations. He completed the MD/PhD Program and completed his medical internship at Thomas Jefferson University in Philadelphia. His focus is on translational cancer research as well as patient-centered care, advocacy, and survivorship for cancer patients.

Monica Fawzy Bryant, Esq is a cancer rights attorney at Triage Cancer Center in Chicago, Illinois. Ms. Bryant is the chief operating officer for Triage Cancer, a national, nonprofit organization that provides education and resources on cancer survivorship issues. Throughout her career, Ms. Bryant has provided hundreds of educational seminars, written articles, and blogs, and appeared on community television and radio shows discussing healthcare-related legal issues. Ms. Bryant is an adjunct law professor at John Marshall School of Law in Chicago, teaching a class on Cancer Rights. Ms. Bryant currently serves on the executive committee of the American Bar Association’s Breast Cancer Task Force. She focuses on disability insurance; employment rights; estate planning and medical decision making; financial health, legislative advocacy; health insurance options; health insurance navigation; and health care reform.

Naifa L. Busaidy, MD is an endocrinologist and associate professor in the Department of Endocrine Neoplasia and Hormonal Disorders at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Busaidy, the director of the Thyroid Nodule Clinic, specializes in thyroid cancer and has authored numerous peer-reviewed research articles and book chapters. Dr. Busaidy is a recipient of a ThyCa thyroid cancer research grant and has spoken at many ThyCa conferences. She is a ThyCa medical advisor. Dr. Busaidy is a 2011 ThyCa research grant recipient.

Maria E. Cabanillas, MD is an oncologic endocrinologist, professor, and the faculty director at the University of Texas MD Anderson Cancer Center in Houston, Texas. She is the faculty director of clinical research in the Department of Endocrine Neoplasia at MD Anderson. As a clinician and clinical researcher, Dr. Cabanillas treats both early and advanced thyroid cancers, including medullary, differentiated, and anaplastic. Her research focus is in advanced and aggressive thyroid cancer and molecular targeted therapies and immunotherapy. She is a principal investigator on several clinical trials for treating advanced disease and has been a member of and currently serves on the board of directors of the International Thyroid Oncology Group (ITOG). She is a ThyCa medical advisor.

Alaina Carr, PhD is a clinical psychologist at Georgetown University in Washington, DC. Dr. Carr received her bachelor’s degree in Psychology from the University of Colorado Boulder and her doctoral in Clinical Health Psychology from the University of Colorado Denver. She also completed the Meaning-Centered Psychotherapy Program for Cancer Care Providers at Memorial Sloan Kettering. Dr. Carr has specialized experience working with cancer patients and their family members (or caregivers) across the cancer care continuum (e.g., diagnosis, treatment, survivorship, and end-of-life). She works with clients to help them better cope with health-related stress.
Speakers & Presenters continued

Ruth Casey, MD is a consultant endocrinologist at Cambridge University Hospital NHS Foundation Trust and senior research associate in the department of medical genetics at Cambridge University in Cambridge, United Kingdom. Dr. Casey leads neuroendocrine tumour (NET) and endocrine cancer services in Cambridge and is the endocrine lead for the endocrine genetics service, encompassing both clinical practice and independently funded research in GIST, phaeochromocytoma and paraganglioma. She has a specialist research interest in SDH deficient tumours and the molecular mechanisms underpinning endocrine cancers. Dr. Casey is also the clinical convener for the Society for Endocrinology Endocrine Cancer Network and a member of the International SDH consortium and an advisor for the patient group AMEND (Association for Multiple Endocrine Neoplasia Disorders).

Francesco S. Celli, MD, MHS is the William G. Blackard Professor of Medicine and chair of the Division of Endocrinology Diabetes and Metabolism at Virginia Commonwealth University (VCU) in Richmond, Virginia. Prior to joining the faculty of VCU, Dr. Celli worked for ten years as clinical investigator at the National Institutes of Health, National Institute of Diabetes Digestive and Kidney Diseases in Bethesda, Maryland. He is a graduate of the University of Rome “La Sapienza”, and a diplomat of the American Board of Internal Medicine, with subspecialty in endocrinology, diabetes, and metabolism. Dr. Celli conducts both clinical and translational research and his scientific interest is focused on the endocrinology and pathophysiology of thyroid hormone action as it relates to energy metabolism. Dr. Celli’s clinical interests are thyroid disease, with a specific focus on thyroid ultrasound, fine needle aspiration biopsy, and multidisciplinary management of thyroid cancer.

Mark S. Chambers, DMD, MS is chief of the section of Oral Oncology and Maxillofacial Prosthetics in the Department of Head and Neck Surgery at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is the vice chair of Research Compliance and Regulatory Affairs. His clinical research efforts include studying the effects of stimulants, antibiotics, and enhancing the body’s immune system to manage dry mouth and injuries to the mouth caused by radiation and/or chemotherapy. Dr. Chambers earned his DMD and an MS in Biological Sciences at the University of Louisville in Kentucky. Dr. Chambers is a ThyCa medical advisor.

Jennifer Choe, MD, PhD is a medical oncologist at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. She earned her medical degree from University of Texas MD Anderson Cancer Center, and completed her internal medicine residency at Baylor College of Medicine. Her hematology/oncology fellowship was completed at Duke University School of Medicine. At Duke she was an assistant professor of medicine, Medical Oncology, and an assistant professor in Head & Neck Surgery & Communication Sciences.

Roger B. Cohen, MD is a professor of medicine at the University of Pennsylvania. He is a graduate of Harvard Medical School and completed internal medicine and hematology training at Mount Sinai Hospital (NY) followed by research fellowships at the Memorial Sloan-Kettering Cancer Center and National Institutes of Health and a medical oncology fellowship at the National Cancer Institute. He was a medical officer at the FDA Center for Biologics from 1989-1994 and was Deputy Director, Division of Monoclonal Antibodies. Prior to his arrival at Penn, Dr. Cohen was Director of the Cancer Center Clinical Trials Office at the University of Virginia Cancer Center in Charlottesville and then Director of the Phase 1 Program at the Fox Chase Cancer Center. He is an active investigator on several first-in-humans clinical trials with research interests that focus on evaluation of novel therapies, including monoclonal antibodies, immune therapies, and small molecule cell-signaling pathway inhibitors. He primarily sees patients with lung and head and neck cancer.

Louise Davies, MD, MS, FACS is an otolaryngologist and associate professor of surgery, Dartmouth Geisel School of Medicine, Hanover, New Hampshire. She is also Chief of Otolaryngology—Head & Neck Surgery. She spent the 2017-2018 academic year as a Fulbright Global Scholar grantees, traveling to Japan and England to do research on thyroid cancer and gain expertise in surgical clinical trial design and implementation. She is best known for her work to define and mitigate the problem of overdiagnosis in thyroid cancer. She is a subject matter expert reviewer for the U.S. Preventive Services Task Force on thyroid cancer screening, on a task force for the International Agency for Research on Cancer, Lyon, France to make recommendations about thyroid monitoring after nuclear accidents, and as an advisor to the state of North Carolina on thyroid cancer cluster evaluation.

Kimberly Davis, PhD is a research associate professor in the Departments of Psychiatry and Oncology and the Director of Psychosocial Oncology in the Lombardi Comprehensive Cancer Center (LCCC) at the Medstar Georgetown University Medical Center in Washington, DC. Dr. Davis received her doctoral degree in clinical health psychology from Washington University in St. Louis, MO. She completed her residency at RUSH St. Luke’s Presbyterian Medical Center in Chicago, IL. At the Lombardi Comprehensive Cancer Center, Dr. Davis provides psychosocial services for patients, families, and survivors throughout the continuum of cancer care.

Caniksha Desai, MD, ECNU is an endocrinologist and clinical assistant professor of endocrinology at Stanford University in Palo Alto, California. She completed her endocrinology fellowship at the Mayo Clinic in Jacksonville, Florida, with an emphasis on the management of patients with thyroid cancer. Dr. Desai’s clinical practice, located in the Endocrinology Clinic Hoover Pavilion, Palo Alto, California, focuses on the management of patients with thyroid diseases, including thyroid nodules and thyroid cancers, and the management of patients with pituitary disorders. She also maintains board certification in neck ultrasonography and internal medicine.

Carlos S. Duque, MD is a head and neck surgeon trained at the University of Miami, Department of Otolaryngology. He works at the Hospital Pablo Tobón Uribe and Clínica las Américas in Medellin, Colombia. Dr. Duque specializes in the treatment and management of thyroid cancer. He has published numerous articles on this topic, as well as a book entitled ¡Uuuuyy, TENGO CANCER DE TIROIDES! Entendiendo la enfermedad y la glándula which is also available in English (Oh no, I HAVE THYROID CANCER!). He has led sessions in both English and Spanish at numerous past ThyCa conferences.

Rosella Elisei, MD is an endocrinologist at University of Pisa in Pisa, Italy. Dr. Elisei is an Associate Professor of Endocrinology at the University of Pisa. She is an expert clinician mainly involved in the management of thyroid cancer patients. Dr. Elisei received numerous international awards: the Light of Life Foundation for the best thyroid cancer researcher of 2011, the 2018 European Thyroid Association award as distinguished scientist in Thyroid research field, the JCME award for the best clinical paper 2006, 2012, 2015 and 2016. Dr. Elisei is the author of 220 papers published in peer-reviewed Journals, 55 manuscripts in proceedings of meetings and book chapters, as well as more than 300 abstracts for national and international meetings. She also serves as a reviewer for several peer-reviewed journals and holds memberships in several professional associations. She is PI of several clinical trials for new target therapy in advanced thyroid cancer.

Laura Fugazza, MD, PhD is an associate professor of endocrinology and the head of the Center of Excellence in the diagnosis and treatment of thyroid cancer at the Istituto Auxologico Italiano IRCCS, Milan, Italy. Dr. Fugazza concentrated her clinical and translational studies on differentiated and medullary thyroid cancer, and on thyroid dyshormonogenesis. She is the associate editor of the European Journal of Endocrinology and the Journal of Clinical Endocrinology & Metabolism. She is also an investigator or principal investigator for phase 3 protocols on TKIs for advanced thyroid cancer. Dr. Fugazza has been one of the coauthors of the Italian consensus on thyroid cancer published in 2018 and the coordinator of the group which produced the 2019 European Thyroid Association Guidelines on advanced thyroid cancer. She is also the leader of the European Thyroid Association Cancer Group (EATA-CG).

Sana Ghaznavi, MD is an endocrinologist and neuroendocrine tumour team lead at Tom Baker Cancer Centre, Calgary, Alberta, Canada. Dr. Ghaznavi is an academic endocrinologist at the University of Calgary, Canada. She graduated from the University of Alberta medical school, completed internal medicine and endocrinology residency at the University of Calgary, and completed an interdisciplinary thyroid cancer fellowship at Memorial Sloan Kettering Cancer Center in New York, NY. Her practice focuses on the management of thyroid cancer patients. Her research interests include active surveillance of papillary microcarcinomas, re-sensitization therapy for radioiodine refractory thyroid cancer, and personalization of thyroid hormone replacement therapy.
Ann W. Gramza, MD is a medical oncologist and associate professor of medicine at Georgetown University specializing in the treatment of head and neck cancer, thyroid cancer, and other rare endocrine malignancies. Dr. Gramza conducts clinical trials with new targeted therapies and immunotherapy drugs. She has considerable experience in thyroid cancer clinical trials, having been previously employed at NIH where she conducted several thyroid cancer clinical trials with novel therapeutic agents.

Jo Grey is the CEO at The Association for Multiple Endocrine Neoplasia Disorders (AMEND), located in Tonbridge, Kent, United Kingdom. Jo ‘fell into’ volunteering for AMEND after being diagnosed with MEN2A in 2000 – the culmination of a dramatic 4-year battle to be diagnosed. Her mother and 2-year-old son were also diagnosed with MEN2A in 2002. Jo has had surgery for two phaeochromocytomas, medullary thyroid cancer and has also lost her left shoulder to an MTC metastasis. In 2013 Jo became AMEND’s first salaried CEO, and manages the charity’s projects, and works informing and supporting all those affected with MEN syndromes and associated rare endocrine conditions. Her wish is that more patients with rare endocrine conditions like MEN survive to live with rather than die from their disease.

Haixia Guan, MD, PhD is an endocrinologist and professor of internal medicine at The First Affiliated Hospital of China Medical University in Shenyang, China. She completed her internal medicine residency and her fellowship training in endocrinology at The First Hospital of China Medical University in Shenyang, China, followed by postgraduate training at the Johns Hopkins Hospital and Boston Medical Center. Dr. Guan’s research interests have been management of thyroid disorders, bone metabolic diseases and tumor-related endocrine problems. She has made more than 80 publications. She was actively involved in three important Chinese guidelines for management of thyroid diseases.

Avital Harari, MD, MSc is an endocrine surgeon and associate professor in the Department of Surgery at the UCLA David Geffen School of Medicine, at the University of California Los Angeles in Los Angeles, California. Dr. Harari received her medical degree with distinction at Washington University School of Medicine in St. Louis, graduating in the top 10% of her medical school class. She trained in general surgery at Columbia University in New York City prior to completing her endocrine surgery fellowship at the University of California, San Francisco. Dr. Harari’s clinical and research interests include the multidisciplinary management of benign and malignant tumors of the adrenal, thyroid, and parathyroid glands as well as the neuroendocrine pancreas. She is also interested in familial endocrine disorders (such as multiple endocrine neoplasia). She offers a wide range of unique services including retroperitoneal or transabdominal laparoscopic adrenalectomy, mini-incision thyroid and parathyroid surgery, central and modified neck dissection, and laparoscopic removal of pancreatic tumors.

R. Alex Harbison, MD, MS is an assistant professor in the Department of Otolaryngology-Head and Neck Surgery at Johns Hopkins University in Baltimore, Maryland. He completed medical school at the University of Colorado followed by residency and a Master of Science at the University of Washington in Seattle. He completed a Head and Neck Surgical Oncology fellowship at Johns Hopkins and is a Head and Neck Endocrine Surgeon Scientist studying the mechanisms by which tumor metabolism dysregulates the anti-tumor immune response. Dr. Harbison is funded through a KL2 grant through the Johns Hopkins Institute for Clinical and Translational Research and an American Head and Neck Society / American Academy of Otolaryngology – Head and Neck Surgery Foundation Young Investigator Combined Award.

Megan R. Haymart, MD is an endocrinologist at the University of Michigan in Ann Arbor, Michigan. Dr. Haymart’s research focuses on variation in the management of thyroid cancer with an emphasis on the role of patients, providers, and health systems in thyroid cancer diagnosis and treatment. She also studies thyroid cancer outcomes and the rise in thyroid cancer incidence. She is principal investigator of the NCI-funded R01 grant “Treatment Decision Making in Low-Risk Thyroid Cancer” and the AHRQ-funded R01 grant “Imaging Practices and Overdiagnosis of Thyroid Cancer.” Dr. Haymart received her medical degree from Johns Hopkins University School of Medicine, completed internal medicine residency at Johns Hopkins Hospital, and completed a fellowship in endocrinology, diabetes, and metabolism at the University of Wisconsin. She participates in creating the National Comprehensive Cancer Network thyroid carcinoma guidelines.

Sharon Hickox, MM, LPMT, MT-BC, CCTS1 is a music therapist at Note-Able Music Therapy Services in Reno, Nevada. Sharon completed a music therapy degree at Saint Mary-of-the-Woods College in 2016. She also has a Master’s of Music from Rice University and a Bachelor’s of Music from the University of Southern California, both in Percussion Performance. She has completed Neurologic Music Therapy training and is a Certified Clinical Trauma Specialist. She has experience working with children, adolescents, and adults to improve mental and physical health concerns as well as intellectual and physical disabilities. She enjoys providing music therapy for patients in pediatric, oncology, neurology, and extended care units.

Ana O. Hoff, MD is an endocrinologist at the University of Sao Paulo Medical School, Sao Paulo, Brazil. Dr. Hoff graduated from the Universidade De Brasilia (Unb) Faculdade De Medicina. She is an associate physician at the Onco Star Clinic Full Member of D’Or Oncology doctor of the clinical staff of Hospital São Luiz Itaim – Rede D’Or. She is also head of the Endocrinology Service of the Cancer Institute of the State of Sao Paulo/ faculty of medicine at the University of Sao Paulo. Dr. Hoff completed her residency in endocrinology and metabolism in the combined program of Baylor College of Medicine and University of Texas MD Anderson Cancer Center. She received her doctorate in endocrinology from the Federal University of Sao Paulo. Dr. Hoff's research focus has included the various types of thyroid cancer, multiple endocrine neoplasia, adrenal carcinoma, osteoporosis, and bone loss in cancer patients.

Jennifer Holkem is a thyroid patient advocate, educator, and founder of “Save Your Thyroid,” a private Facebook community and future nonprofit organization for patients pursuing nonsurgical treatment options for thyroid nodules. In 2019 she was searching for an alternative to surgery for her own thyroid nodules and discovered radiofrequency ablation (RFA). Due to a severe lack of patient-oriented resources on this and other thermal ablation procedures, she created her YouTube channel, “It’s me Jen again,” where she shares her own experience and creates educational video content on this topic. She is a passionate educator and advocates for patients and doctors to save the thyroid whenever possible.

Mimi I. Hu, MD is an endocrinologist and professor at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Hu has served on the faculty at MD Anderson Cancer Center since 2007. Her clinical expertise is in the evaluation and treatment of patients with papillary, follicular, and medullary thyroid cancers, hereditary endocrine neoplasia disorders, and metabolic bone and mineral disorders. She is the primary investigator and collaborator on multiple clinical trials evaluating various targeted therapies for advanced thyroid cancer. Dr. Hu has published articles and book chapters evaluating the management of medullary thyroid cancer, multiple endocrine neoplasia, bone health in cancer patients, endocrine complications of head and neck surgery, and paraneoplastic endocrine disorders. Dr. Hu is a ThyCa medical advisor.

Jacqueline Jonklaas, MD, PhD, MPH is an endocrinologist at MedStar Georgetown University Medical Center in Washington, D.C. Dr. Jonklaas obtained her MD, residency, and fellowship training at Georgetown University. Dr. Jonklaas is the director of the Georgetown Clinical Research Unit and has published research regarding treatment and outcomes in patients with thyroid cancer. She is the chief operating officer of the American Thyroid Association. She has been a member of the Endocrine Society since 1997 and serves on the editorial board of the Journal of Clinical Endocrinology and Metabolism and as a member of the Endocrine Society Self-Assessment Committee.

Shoko Kure, MD, PhD is a is a post-doctoral research fellow in Dr. Carmelo Nucera's preclinical thyroid cancer research lab at Beth Israel Deaconess Medical Center, Harvard Medical Center, in Boston, Massachusetts. Dr. Kure has a background of diagnostic pathology/cytology, molecular/experimental pathology. She received her medical degree and PhD (pathology) from Nippon Medical School, Tokyo, Japan. After the residency, she became a junior faculty member in the Department of Pathology at Nippon Medical School and published several peer-reviewed papers. Her subspecialty is thyroid pathology, and her current research interest is in the tumor microenvironment of medullary thyroid cancer. She is a new member of the American Thyroid Association (ATA), declaring that she will dedicate herself to this research, provide new evidence to the ATA, and contribute to the ATA as well as persistent MTC patients with better treatment and diagnostic method. Dr. Kure is a 2022 ThyCa research grant recipient.
Tom Kurzawinski, MD, PhD FRCS is a consultant pancreatic and endocrine surgeon at the University College Hospital, Royal Free Hospital and Great Ormond Street Hospital in London, England. He earned his medical degree and received training in general surgery in Poland. Dr. Kurzawinski continued specialist training and research in liver, pancreas and endocrine surgery in the United Kingdom. He is a fellow of the Royal College of Surgeons of Edinburgh and a member of British Association of Thyroid and Endocrine Surgeons, British Society for Endocrinology and Paediatric Society. He established the Centre for Endocrine Surgery which provides surgical treatments for children and adult patients with diseases of the endocrine glands.

Jennifer Kwak, MD is a nuclear medicine physician at the University of Colorado Hospital in Aurora, Colorado. Dr. Kwak also serves as an Associate Professor of Radiology-Nuclear Medicine and the Nuclear Radiology Fellowship Program Director. She earned undergraduate degree from Dartmouth College, and her medical degree from Tufts University School of Medicine in Boston, MA.

Theodore W. Laetsch, MD, is a pediatric oncologist at Children’s Hospital of Philadelphia in Philadelphia, Pennsylvania. He leads both the Developmental Therapeutics Program (DVL) and the Very Rare Malignant Tumors Program (VRMTP), as well as holding national leadership roles in each of these areas within the Children’s Oncology Group (COG). In the DVL program, Dr. Laetsch conducts early phase clinical trials of new treatments for children with difficult to treat cancers, with a particular area of focus including molecularly targeted therapies that are designed to block specific genetic mutations identified in patients’ tumors. Dr. Laetsch leads the pediatric development of TRK inhibitors for children with NTRK gene fusions, and now leads a COG nationwide clinical trial studying the ability to use TRK inhibitors instead of chemotherapy for children with one of these gene fusions.

Amanda LaGreca, MD is an endocrinologist and assistant professor of medicine at the University of Colorado School of Medicine in Aurora, Colorado. She received her medical degree from University of Buenos Aires and completed her residency at Yale-New Haven Medical Center in Connecticut.

Jessie Larson-Wu, MA, LPC Jessie has been a mental health therapist for almost 10 years and is a recent survivor of papillary thyroid cancer. She recently started a podcast called “support through thyroid cancer” to provide support through storytelling and wisdom sharing between folks with a thyroid cancer diagnosis. Her current clinical practice is at a university counseling center providing services to students.

Michael A. Levine, MD, FAAP, FACP, FACE is chief of the Division of Endocrinology and Diabetes and Director of the Center for Bone Health at The Children’s Hospital of Philadelphia. He is a Professor of Pediatrics and Medicine at the University of Pennsylvania Perelman School of Medicine, and he holds the Lester Baker Endowed Chair in Pediatric Diabetes. His primary clinical interests are endocrine diseases that affect bone and mineral metabolism, particularly osteoporosis, primary hyperparathyroidism, hypoparathyroidism, rickets, and genetic bone disease. He has identified the molecular basis of several inherited disorders of mineral metabolism. His research interests extend to the molecular basis for embryological development of the parathyroid glands.

Jochen H. Lorch, MD, MSC is a medical oncologist and professor of medicine and medical director of the Head and Neck and Thyroid Programs Northwestern Medical Group in Chicago, Illinois. He graduated from the University of Regensburg in Germany in 1993 and completed his internship and residency at the University of Pennsylvania/Presbyterian Medical Center in 1999. He was awarded a fellowship in hematology and oncology at Northwestern University in Chicago. In 2002, he returned to Germany to complete his German Board Certification in Internal Medicine and Medical Oncology. He returned to the US in 2005 to take a faculty position at Boston University in Boston, MA and started as a faculty member at Dana Farber Cancer Institute in Boston, MA in 2008. He became the inaugural director of the Thyroid Center at Dana Farber. In 2021 he left Dana Farber as Associate Professor of Medicine to join the faculty at Northwestern University. Dr. Lorch is a ThyCa medical advisor.

Iftikhar A Malik MD, ECNU, FACE is an endocrinologist in Appleton, Wisconsin. Dr. Malik earned his medical degree at Punjab Medical College and completed residency training in pulmonary medicine at DHQ Hospital, both in Pakistan. He received residency training in internal medicine at Kingsbrook Jewish Medical Center in New York and served as the chief medical resident during his studies there. Dr. Malik completed a fellowship program in endocrinology through the Medical College of Wisconsin. He is a great proponent of least invasive techniques and provides Ethanol ablation and Laser ablation for nonmalignant enlarging thyroid nodules.

Haggai Mazeh, MD, FACS, FISA is an endocrine surgeon at Hadassah Medical Center in Jerusalem. He is chairman of the Israel Endocrine Surgery Society and the Chief-of-Surgery at the Department of Surgery, Hadassah Medical Center, Mount Scopus, Jerusalem, Israel. Prof. Mazeh completed his general surgery residency at Hadassah Medical Center and his endocrine surgery fellowship at the University of Wisconsin. He is currently leading a high-volume Endocrine Surgery service and performs numerous thyroid, parathyroid, adrenal, and neuroendocrine surgeries. Prof. Mazeh has multiple and significant scientific contributions in Endocrine Surgery. His research is presented at national and international conferences and is published at high impact factor journals.

Lizzy McAninch, MD is an endocrinologist and clinical associate professor at Stanford Hospital and Clinics in Stanford, California. She received her medical degree from University of Miami Miller School of Medicine. Her research focuses on understanding aspects of thyroid hormone metabolism and genetic differences that impact these pathways.

David G. McFadden, MD is an endocrinologist at UT Southwestern Medical Center in Dallas, Texas. Dr. McFadden is an assistant professor of internal medicine and biochemistry. His clinical interest is in the treatment of tumors arising from endocrine glands, including thyroid cancer. He is a member of the American Thyroid Association and the International Thyroid Oncology Group and has been awarded research grants from the National Institutes of Health, American Thyroid Association, the Disease Oriented Clinical Scholars (DOCS) program at UT Southwestern, and the Cancer Prevention and Research Institute of Texas (CPRIT). His current research focuses on using genetic engineering and chemical screens to discover new treatments for cancer.

Beverly McLaughlin, MA is a patient navigator at the University of Colorado Hospital in Aurora, Colorado. Ms. McLaughlin is a member of the administrative staff in the Division of Endocrinology, Diabetes, and Metabolism.

David Myssiorek, MD, FACS is an otolaryngologist at Bronxcare Health System in Bronx, New York. He is the author of numerous articles on thyroid cancer surgery and other head and neck surgery. A graduate of New York University School of Medicine, Dr. Myssiorek did his internship at Lenox Hill Hospital and was Chief Resident at New York University/Bellevue. He is the author of numerous articles on thyroid cancer surgery and other head and neck surgery. Dr. Myssiorek is a ThyCa medical advisor.

Caroline Nguyen, MD is an endocrinologist and an assistant professor of clinical medicine in the Division of Endocrinology, Diabetes, and Metabolism and the Department of Obstetrics and Gynecology at Keck Medical Center of USC in Los Angeles, California. Her clinical and research interests are related to the diagnosis and treatment of thyroid disease with a special focus on thyroid disorders in pregnancy including hyperthyroidism, hypothyroidism, subclinical thyroid disease, thyroid cancer, Hashimoto’s, and postpartum thyroiditis. She has published articles in Thyroid, the Journal of Clinical Endocrinology and Metabolism, Clinical Obstetrics and Gynecology, and Clinical Diabetes and Endocrinology.

Theodora Pappa, MD, PhD is an onco-endocrinologist and physician scientist committed to precision medicine in thyroid cancer. Her clinical practice at Brigham and Women's Hospital/Dana-Farber Cancer Institute is thyroid focused and she conducts translational research on thyroid cancer genomics collaborating with colleagues from Harvard Medical School and the Broad Institute. The focus of her research activities is to chart the tumor ecosystem in thyroid cancer and leverage the advances of next generation sequencing and novel computational approaches in order to dissect and clinically interpret thyroid cancer genome, and eventually develop novel prognostic biomarkers to help advance thyroid cancer care. Dr. Pappa is a 2022 ThyCa research grant recipient.
Susan Pitt, MD, MPH is an associate professor of surgery and director of Endocrine Surgery Health Services Research at the University of Michigan in Ann Arbor, MI. Dr. Pitt’s clinical practice focuses on surgical treatment of thyroid, parathyroid, and adrenal gland disease. Dr. Pitt’s research is funded by the National Cancer Institute and focuses on improving patient outcomes, patient-doctor communication, and treatment decision making, while reducing unnecessary care for patients with thyroid cancer. To facilitate this work, Dr. Pitt founded the CHOICE Collaborative to Compare Healthcare Outcomes in Cancer Experience. Dr. Pitt received her medical degree from the Medical College of Wisconsin and her Master’s in Population Health Science from Washington University in St. Louis. She completed her general surgery residency at Washington University in St. Louis and an Endocrine Surgery fellowship at Brigham and Women’s Hospital in Boston, MA.

Eyal Robenshtok, MD is an endocrinologist at Beilinson Hospital and Davidoff Cancer Center in Petah Tikva, Israel. He graduated from the Hadassah Medical School in Jerusalem with his MD degree and completed his training in internal medicine and endocrinology at the Rabin Medical Center. In 2012 he completed the thyroid cancer fellowship at Memorial Sloan-Kettering Cancer Center, New York. Dr. Robenshtok believes in compassionate, state of the art medical treatment, with shared decision making to achieve the best goals for each individual patient. His research focuses on individualized, risk stratified management of thyroid cancer, and his studies were published in leading scientific journals, including JCEM, Thyroid and more. He is an active member of these professional organizations: ATA, ETA, IES, EORTC and ITOG.

Bruce Robinson, MD is an endocrinologist and professor at the University of Sydney, Sydney, Australia. He has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital, since 1989. He has been chairman Hoc Mai Foundation, a major program in medical and health education and exchange with Vietnam since 2001. In 2015 Dr. Robinson was appointed as chair of Australia’s peak advisory and funding body for medical research, National Health and Medical Research Council. His research has focused on identifying genetic changes which either predispose or directly cause endocrine tumors, and among other highlights has been the formation of an international consortium of families from around the world to study medullary thyroid carcinoma and pheochromocytoma.

Mabel Ryder, MD is an endocrinologist at the Mayo Clinic in Rochester, Minnesota. She earned her medical degree from the University of Texas and completed her fellowship and residency at the University of Cincinnati College of Medicine. Dr. Ryder specializes in head and neck cancer and nuclear medicine therapy. She has contributed to many publications on thyroid cancer. Dr. Ryder is a 2007 ThyCa research grant recipient.

Anna Sawka, MD, PhD is a clinician scientist and endocrinologist at Toronto General Hospital Research Institute in Toronto, Canada. Dr. Sawka was recently promoted to professor in the Division of Endocrinology, Department of Medicine at the University of Toronto. She holds a PhD in Health Research Methodology/Biostatistics and Epidemiology from McMaster University. Her research focus is primarily in thyroid cancer.

Donna Sherman, MSW, LCSW is a clinical social worker and thyroid cancer survivor based out of Highland, New York and New York City. Since 2008 she has been working as a behavioral health coach and consultant offering skills-based guidance and training that helps clients live and work well. In 2016 she created the therapeutic guided restorative recording titled: Yoga Nidra: Total Relaxation Practices for Adults & Teens. Ms. Sherman currently hosts the Sparks In Action Podcast.

Donald L. Siegel, MD, PhD is Professor of Pathology & Laboratory Medicine and Director of Transfusion Medicine & Therapeutic Pathology at the University of Pennsylvania. He is medical director of the blood bank, apheresis unit, and stem cell laboratory, and director of Penn’s Center for Advanced Cellular Therapies which developed and administered to patients the first successful chimeric antigen receptor T cells (CAR-T) therapies for leukemia and first-in-human use of CRISPR-edited cells. Dr. Siegel received an undergraduate degree in biophysics from Brown University, a Ph.D. in biophysics from Harvard University, and an M.D. from the University of Pennsylvania School of Medicine. After clinical pathology residency and fellowship training in blood banking/transfusion medicine, he joined the faculty at UPenn. Dr. Siegel’s translational research laboratory focuses on the discovery of recombinant antibodies relevant to benign hematologic, infectious diseases, and oncology, particularly for the design of novel CAR-T therapies.

Bryn Silverman is a filmmaker and graduate of the University of Southern California School of Cinematic Arts. She is an Associate Programmer for the Tribeca Film Festival. Her work examines myth making in American history. She was a story producer for Netflix’s documentary series Amend: The Fight for America and an editor of the critically acclaimed documentary film Roll Red Roll. She is currently producing a film that follows her experience with papillary thyroid cancer.

Grant M. Smith, MD is a clinical assistant professor of medicine at the Stanford School of Medicine, where he works on the inpatient palliative care consult service and in the outpatient palliative care clinic. He is the medical director of the Stanford Palliative Care Community Partnerships Team, which raises awareness and understanding of palliative care in the community. He received his medical degree from Harvard Medical School and completed internal medicine residency and palliative care fellowship at the University of California, San Francisco.

Julie Ann Sosa, MD, MA, FACS, FSSO is an endocrine and oncologic surgeon at the University of California, San Francisco in San Francisco, California. She is also Chair, Department of Surgery and Professor in the Departments of Surgery and Medicine. Her previous position was at Duke University Medical Center in Durham, North Carolina. She is a principal investigator or co-principal investigator of studies of new drug treatments for differentiated thyroid cancer (papillary/follicular), medullary thyroid cancer, and anaplastic thyroid cancer. Following undergraduate education at Princeton University, she received an MA in Human Sciences at the University of Oxford in the United Kingdom and her medical degree from Johns Hopkins University School of Medicine in Baltimore, Maryland. She received postgraduate training at Johns Hopkins Hospital as well as John Radcliffe and Churchill Hospitals in Oxford, England. Dr. Sosa is a ThyCa medical advisor.

Susan Spinosa is the founder and president of NTRKers.org. Susan is a thyroid cancer survivor since 2004. In 2018, Susan was diagnosed with NTRK gene fusion positive thyroid cancer. Her main focus has been education and connecting patients, family, and care partners for those affected by any NTRK positive cancer. She feels it is also important to advance medical community education and the importance of biomarker tumor testing. In addition, Susan is a volunteer with the ThyCa: Thyroid Cancer Survivors’ Association, Inc., Cancer Hope Network and the Biomarker Collaborative.

Christine Spitzweg, MD is an endocrinologist at Medizinische Klinik und Poliklinik IV in Munich, Germany. Dr. Spitzweg is a professor of medicine at the Department of Internal Medicine II, Ludwigs-Maximilians-University (LMU) Munich Campus Grosshadern. She obtained her medical degree from the Munich Medical School, LMU Munich. She received her MD at the University of Oxford in 2001. Dr. Spitzweg has been involved in both clinical practice and research with a special interest in benign and malignant thyroid disease. She directs the research laboratory for Molecular Endocrinology investigating expression and regulation of the sodium iodide symporter (NIS) in and outside of the thyroid gland, the role of NIS as a novel reporter and therapy gene in the management of non-thyroidal and thyroidal cancer as well as regulation of mesenchymal stem cell tumor homing and differentiation by thyroid hormones.

Cord Sturgeon, MD, MS is the chief endocrine surgery at Northwestern University Feinberg School of Medicine in Chicago, Illinois. He also serves as a physician Director of Informatics for the NMHC system since 2015. He completed his residency at the University of Illinois Hospital, and his fellowship at the University of California San Francisco Medical Center. His academic focus was clinical outcomes for thyroid cancer, hyperparathyroidism, and adrenal tumors including pheochromocytoma and adrenal cancers. Dr. Sturgeon’s clinical focus is the treatment of thyroid and parathyroid disease. He has a special interest in Multiple Endocrine Neoplasia.
Speakers & Presenters continued

Vivek Subbiah, MD is a clinical trialist and physician investigator at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is an associate professor in the Investigational Cancer Therapeutics department. He is the Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine division. Dr. Subbiah has a unique training background as he is one of the few physicians in the nation/world to have training in oncology in both adults and children. He is board certified in both Internal Medicine and Pediatric Oncology and completed fellowships in both adult and pediatric oncology at MD Anderson. He is primarily involved in translational cancer research and the design and conduct of early-phase biomarker-driven clinical trials, with a specialist interest in anti-body drug conjugates, radio-pharmaceuticals, immunocongjugates and basket trials.

Vineeth K. Sukrithan, MD is a medical oncologist and assistant professor in the Division of Medical Oncology at Ohio State University Comprehensive Cancer Center in Columbus, Ohio. Dr. Sukrithan is a member of the Translational Therapeutics Program at the OSUCCC and the co-director of the Adrenal Tumor Clinic. He was recently selected to lead an externally funded effort through the International Thyroid Oncology Group to operationalize a multi-institutional registry database for patients with medullary thyroid cancer.

Valentina D. Tarasova, MD is an endocrinologist at Moffitt Cancer Center in Tampa, Florida. Dr. Tarasova received her MD at Kubansky State Medical University. She completed an internal medicine residency at Yale New Haven Hospital, Yale School of Medicine, New Haven, CT and an endocrinology, diabetes and metabolism fellowship at the University of Omaha, NE. Most recently, Dr. Tarasova has completed a thyroid cancer fellowship at Memorial Sloan Kettering Cancer Center. Dr. Tarasova’s clinical interests include thyroid neoplasm, particularly diagnosis, monitoring and treatment of thyroid carcinoma (from low risk to advanced progressive forms of thyroid cancer). Her research interests include the role of molecular markers in diagnosing and determining the prognosis of thyroid neoplasm, risk stratification of patients with thyroid cancer and developing tools to estimate the prognosis and determine the management of patients with thyroid cancer.

Ralph P. Tufano, MD is an otolaryngologist at Sarasota Memorial Health Care System in Sarasota, Florida. Dr. Tufano is the Medical Director of Head and Neck Endocrine Surgery at Sarasota Memorial’s First Physicians Group Thyroid and Parathyroid Center. Dr. Tufano specializes in thyroid and parathyroid surgery including the management of hyperparathyroidism, thyroid nodules, early, advanced and recurrent thyroid cancer, neck lymph node metastases, goiter and Graves’ disease. His expertise and novel treatment techniques have helped personalize treatment and improve surgical outcomes for patients with these conditions. From 2009-2015, he directed the Johns Hopkins Hospital Multidisciplinary Thyroid Tumor Center.

R. Michael Tuttle, MD is an endocrinologist at Memorial Sloan-Kettering Cancer Center in New York, New York. Dr. Tuttle is also a professor of medicine at the Joan and Sanford I. Weill Medical College of Cornell University. Dr. Tuttle’s research projects in radiation-induced thyroid cancer have taken him from Kwajalein Atoll in the Marshall Islands to the Hanford Nuclear power-plant in Washington State to regions in Russia that were exposed to fallout from the Chernobyl accident. He served on the American Thyroid Association committee that produced the current guidelines for the management of benign and malignant thyroid nodules. He also chaired the National Comprehensive Cancer Network Thyroid Cancer panel and served on the Endocrinologic and Metabolic Drugs advisory committee of the U.S. Food and Drug Administration. Dr. Tuttle is a ThyCa medical advisor.

Danica Vodopivec, MD is an oncologic endocrinologist and assistant professor of medicine at The University of Alabama at Birmingham, Department of Endocrinology, Diabetes and Metabolism in Birmingham, Alabama. After obtaining her medical degree at Universidad de Guayaquil in Ecuador, she completed an Internal Medicine residency at Lahey Clinic/Tufts University in Burlington, MA. She did her Endocrinology fellowship at Boston Medical Center/Boston University School of Medicine in Boston, MA followed by an oncologic endocrinology specialty fellowship at The University of Texas MD Anderson Cancer Center, Houston, TX. Throughout her training years she has participated in clinical and bench research dedicated to parathyroid neoplasia, multiple endocrine neoplasia syndrome, and tyrosine kinase inhibitors resistance mechanisms in thyroid cancer. Her scholarly activities have resulted into several peer-reviewed articles, book chapters, and quality improvement projects dedicated to better serve the community of patients presenting with various types of endocrine neoplasia, in particular advanced thyroid cancer.

Jonathan Wadsley, MA, MRCP, FRCR is an oncologist at Weston Park Hospital, in Sheffield, United Kingdom. He also serves as professor, Department of Oncology and Metabolism, University of Sheffield. His clinical interests are in thyroid cancer, neuroendocrine tumours and pancreatic/duodenal tract cancers. He is a member of the Sheffield European Neuroendocrine Tumour Society Centre of Excellence team and provides clinical leadership for the Sheffield molecular radiotherapy service. Dr. Wadsley is the academic director for the directorate of Specialised Cancer Services and Clinical Director of the Sheffield Cancer Clinical Trials Centre. He has numerous national roles, including NIHR National Specialty Lead for Radiotherapy and Imaging, NIHR Cluster co-lead, chair of the NCRI Thyroid Cancer Group, and a member of ARSAC.

Zhuoying Wang MD, PhD is an endocrinologist and professor and chief of the Department of Head and Neck Surgery, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, in Shanghai, China. Dr. Wang graduated from Fudan University Shanghai Medical School in 2000. He completed his surgical oncology residency and fellowship training in Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center in Shanghai, China. He completed research training at the University of Texas MD Anderson Cancer Center in Houston. He is member of American Head and Neck Society (AHNS) and American Association of Clinical Endocrinologists (AACE). He serves as President-elect of Thyroid cancer Committee in Chinese Society of Clinical Oncology (CSCO). He has been actively involved in several Chinese guidelines for management of thyroid diseases.

Jonathan Wasserman, MD, PhD is a pediatric endocrinologist and associate professor at The Hospital for Sick Children, Toronto, Ontario, Canada. He also serves as a project investigator of genetics and genome biology at the Research Institute. Dr. Wasserman’s research focuses primarily on pediatric thyroid cancer and spans both clinical and translational domains. His research includes genetics and genomics of pediatric papillary thyroid cancer, health care utilization patterns among young patients with thyroid cancer at diagnosis and during follow-up and the identification of prediction models to improve assessment of thyroid nodules in children and to gauge malignant potential. He received his medical training at Harvard Medical School and the Massachusetts Institute of Technology and subsequently pursued an internship and residency in pediatrics at Children’s Hospital in Boston. He previously earned a PhD and completed postdoctoral training in genetics at the University of Cambridge, England. Dr. Wasserman serves as co-chair of the American Thyroid Association’s (ATA) Pediatric Thyroid Cancer Guidelines.

Linwah Yip, MD is an associate professor of surgery in the Division of Breast/Endocrine Surgery and Surgical Oncology, and holds a secondary appointment with the Clinical and Translational Science Institute at the University of Pittsburgh. Her research and clinical interest are the utility of molecular markers to guide management of indeterminate thyroid nodules and to direct extent of surgery for thyroid cancer. She is the program director for Complex General Surgical Oncology Fellowship and is the Co-Chief of the Division of Endocrine Surgery.

Mark E. Zafereo, MD is a head and neck surgeon and associate professor at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is section chief of head and neck oncology surgery and associate medical director of the Endocrine Center. He holds national committee appointments for professional associations and is past president of the Houston Society of Otolaryngology-Head and Neck Surgery. His clinical practice focuses on patients with thyroid cancer and parathyroid neoplasms. Dr. Zafereo is a ThyCa medical advisor.
THANK YOU to all of ThyCa’s Volunteers

who give so many hours of your time and talents.

Our heartfelt Thank You to our more than 400 volunteers, who:

• Answer emails to thyca@thyca.org and our other ThyCa emails, and calls to our Toll-Free Number
• Lead Local Support Groups throughout the United States and in Ireland
• Oversee our Online Communities: 11 Email Support Groups, Facebook, Inspire, Instagram, LinkedIn, Pinterest, Snapchat, Twitter, & YouTube
• Give one-to-one support, matched by type of thyroid cancer, in our Person-to-Person Network
• Expand and update our website and develop our publications in English, Arabic, Chinese, French, Greek, Hebrew, Italian, Japanese, Portuguese, Russian, and Spanish
• Organize our Conferences, Workshops, Seminars, plus our online Webinars
• Give and post materials in community locations and health care settings
• Represent ThyCa at medical meetings, cancer awareness events, community health fairs, television broadcasts, health and human services conferences, and other events.
• Raise awareness of thyroid cancer and the importance of neck checks and early detection, treatment, and lifelong follow-up
• Build and strengthen relationships with medical professionals, associations, other cancer survivorship organizations, and community groups
• Raise funds and in-kind donations to support our services and thyroid cancer research
• Get involved in Thyroid Cancer Awareness Month in person, online, and by mail
• Reach out throughout the year in community groups and the media to support survivors and families locally, regionally, and worldwide and to educate the public about thyroid cancer
• Serve in many key roles: Team Leadership, Volunteer Training and Encouragement, Mailings, Recordkeeping, Financial Transactions, Filing, and more

We welcome new volunteers, for one-time projects and for ongoing volunteering. Learn more in the How To Help section of www.thyca.org

In Honor of Our Caregivers

We honor the families and friends of thyroid cancer survivors. You give us your support and love in countless ways. As patients, struggling through our thyroid cancer journey, we realize how difficult it is for you, too. It takes courage to stare down cancer, both as a patient and as the one standing by.

Thank you for facing it with us.

Helpful Links

Papillary/Follicular Thyroid Cancer
www.thyca.org/pap-fol

Medullary Thyroid Cancer
www.thyca.org/mtc

Anaplastic Thyroid Cancer
www.thyca.org/atc

Pediatric Thyroid Cancer
www.thyca.org/pediatric

Inspire – 91,494 Members

ThyCalnc – 28,000 Followers

@ThyCalnc – Over 5,400 Followers

ThyCalnc – Over 5,000 Followers

ThyCalnc – Over 200 Friends

ThyCalnc – Over 400 Followers

ThyCalnc – Over 850 Connections

5,000+ Subscribers,
Over 500,000 Views

Over 400 Likes
ThyCa's Research Fundraising and Grants

ThyCa: Thyroid Cancer Survivors' Association, Inc., and our community have joined together to raise funds for thyroid cancer research. Together, we are able to make a tremendous difference!

Our goal is cures for all thyroid cancer. We support research on all types of thyroid cancer — papillary, follicular, medullary, and anaplastic. Our Research Funds welcome all contributions, of any size.

Our Research Grants are open to all researchers and institutions, worldwide. Independent expert panels of the American Association of Endocrine Surgeons (AAES) and the American Thyroid Association (ATA) evaluate the grant proposals and select projects to be funded.

In 2003, ThyCa proudly awarded our first thyroid cancer research grant. We award grants each year. In 2022 we awarded 8 grants. Our grant recipients are from these institutions:

- Cancer Center Karolinska, Sweden
- Children's Hospital of Philadelphia, Pennsylvania
- Cochin Institut, France
- Columbia University, New York, New York
- Dana-Farber Cancer Institute, Massachusetts
- Duesseldorf University Hospital, Germany
- Duke University, North Carolina
- Gustave Roussy, France
- Harvard Medical School & Beth Israel Deaconess Medical Center, Massachusetts
- Harvard Medical School & Brigham and Women’s Hospital, Boston, Massachusetts
- Johns Hopkins Medical School, Maryland
- Massachusetts General Hospital/Harvard Medical School, Massachusetts
- MedStar Georgetown University Hospital, District of Columbia
- Medstar Washington Hospital Center, Washington, DC
- MedStar Washington Hospital Center/MedStar Georgetown University, District of Columbia
- Memorial Sloan-Kettering Cancer Center, New York
- National Cancer Institute/National Institutes of Health, Maryland
- National University of Cordoba, Argentina
- New York University Langone Medical Center, New York
- Ohio State University, Columbus, Ohio
- Ohio State University, Ohio, and Medical University of Gdansk, Poland
- Penn State Hershey Cancer Institute, Pennsylvania
- Phoenix VA Health Care System, Arizona
- Providence Portland Cancer Center, Oregon
- Tulane University School of Medicine, Louisiana
- University Hospital Basel, Basel, Switzerland
- University of Arkansas for Medical Sciences, Arkansas
- University of California, Los Angeles, and Veterans Affairs West Los Angeles Health Care System, California
- University of Birmingham, United Kingdom
- University of Colorado, Aurora, Colorado
- University of Texas Southwestern, Texas
- Vanderbilt University Medical Center, Tennessee
- Washington University School of Medicine, St. Louis, Missouri
- Weill Medical College of Cornell University, New York, New York

Realizing that every mighty tree begins with a single seed, and that every seed planted by human hands begins with elements of both hope and faith, ThyCa planted this seed in the hope that it will grow strong and tall, and with the faith that others will answer the call and help nurture its growth.

We invite you to join us in our quest to find cures for Thyroid Cancer. Our heartfelt thanks!
ThyCa is fortunate to have a distinguished Medical Advisory Council of 57 members with expertise in thyroid cancer. This board provides valuable counsel and supports our goals in education, treatment, and research. More than 50 distinguished specialists provide ongoing review and input for our website and materials. Thank you.

Erik K. Alexander, MD, Endocrinologist, Brigham and Women’s Hospital, MA

Peter Angelos, MD, PhD, Endocrine Surgeon, University of Chicago, IL

Douglas W. Ball, MD, Endocrinologist, Johns Hopkins Medicine, MD

Andrew J. Bauer, MD, Pediatric Endocrinologist, The Children’s Hospital of Philadelphia, PA

Keith C. Bible, MD, PhD, Oncologist, Mayo Clinic, MN

Marcia S. Brose, MD, PhD, Oncologist, Thomas Jefferson University, PA

Kenneth D. Burman, MD, Endocrinologist, MedStar Washington Hospital Center, Washington, D.C.

Naïfa L. Busaïdy, MD, Endocrinologist, University of Texas, MD Anderson Cancer Center, TX

Maria E. Cabanillas, MD, Endocrinologist, University of Texas, MD Anderson Cancer Center, TX

Mark S. Chambers, DMD, MS, Dentist/Oral Oncologist, University of Texas, MD Anderson Cancer Center, TX

Gary L. Clayman, DMD, MD, FACS, Thyroid Cancer Surgeon, Clayman Thyroid Cancer Center, FL

Ezra E.W. Cohen, MD, Oncologist, Moores Cancer Center in San Diego, CA

Jeffrey A. Cooper, MD, Nuclear Medicine Physician, WIRB-Copernicus Group Princeton, NJ

Gilbert J. Cote, PhD, Molecular Geneticist, University of Texas, MD Anderson Cancer Center, TX

Gary L. Francis, MD, PhD, Endocrinologist, University of Texas Health Science Center at San Antonio, TX

Robert F. Gagel, MD, Endocrinologist, University of Texas, MD Anderson Cancer Center, TX

Andrew G. Gionoukakis, MD, Endocrinologist, UCLA School of Medicine, CA

David Goldenberg, MD, Head and Neck Surgeon, Penn State Hershey Medical Center, PA

Ann W. Gramza, MD, Oncologist, MedStar Georgetown University Hospital, Washington, D.C.

Elizabeth G. Grubbs, MD, Surgeon, University of Texas, MD Anderson Cancer Center, TX

Janis I. Halzel, PharmD, Pharmacist, Halzel and Associates, CO

Bryan R. Haugen MD, Endocrinologist, University of Colorado Health Sciences Center, CO

Mimi I. Hu, MD, Endocrinologist, University of Texas, MD Anderson Cancer Center, TX

Paul W. Ladenson, MD, Endocrinologist, Johns Hopkins Medicine, MD

Stephanie L. Lee, MD, PhD, Endocrinologist, Boston Medical Center, MA

Jochen H. Lorch, MD, MSc, Medical Oncologist, Northwestern Medical Group Chicago, IL

Donald Margouleff, MD, Nuclear Medicine, North Shore University Hospital, NY

Bryan McVier, MB, ChB, PhD, Endocrinologist, Moffitt Cancer Center, FL

Mira M. Milas, MD, Endocrine Surgeon, Banner – University Medical Center of Phoenix, AZ

David Myssiorek, MD, Otalaryngologist, Bronxcare Health System, NY

Barry D. Nelkin, PhD, Researcher, Johns Hopkins Medicine, MD

Yuri E. Nikiforov, MD, PhD, Pathologist, University of Pittsburgh Medical Center, PA

Sareh Parangi, MD, Surgeon, Massachusetts General Hospital, MA

Gregory W. Randolph, MD, Otalaryngologist, Massachusetts Eye and Ear Infirmary, MA

Scot C. Remick, MD, Medical Oncologist, Maine Medical Center Cancer Institute, ME

Matthew D. Ringel, MD, Endocrinologist, The Ohio State University Comprehensive Cancer Center, OH

Benjamin R. Roman, MD, MSHP, Head & Neck Surgeon, Memorial Sloan-Kettering Cancer Center, NY

Martin Schlumberger, MD, Endocrinologist, Institute Gustave Roussy, France

Pamela Schultz, PhD, RN, MS, Nursing Professor/Researcher, New Mexico State University, NM

Manisha H. Shah, MD, Oncologist, Hematologist, The Ohio State University College of Medicine, OH

Eric J. Sherman, MD, Oncologist, Memorial Sloan-Kettering Cancer Center, NY

Steven I. Sherman, MD, Endocrinologist, University of Texas, MD Anderson Cancer Center, TX

Peter A. Singer, MD, Endocrinologist, University of Southern California Keck School of Medicine, CA

Jennifer A. Sipos, MD, Endocrinologist, The Ohio State University College of Medicine, OH

Monica C. Skarulis, MD, Endocrinologist, National Institutes of Health, MD

Robert C. Smallridge, MD, Endocrinologist, Mayo Clinic, FL

Julie Ann Sosa, MD, MA, Surgeon, University of California at San Francisco, CA

Carole A. Spencer, PhD, FACB Thyroglobulin Researcher, University of Southern California Endocrine Services Laboratory, CA

David Steward, MD, FACS, Otolaryngologist, University of Cincinnati College of Medicine, OH

Ralph P. Tufano, MD, MBA, FACS, Endocrine Surgeon, Sarasota Memorial Health Care System Sarasota, FL

R. Michael Tuttle, MD, Endocrinologist, Memorial Sloan-Kettering Cancer Center, NY

Douglas Van Nostrand, MD, Nuclear Medicine Physician, MedStar Washington Hospital Center, Washington, D.C.

Steven G. Waguespack, MD, Endocrinologist, University of Texas, MD Anderson Cancer Center, TX

Leonard Wartofsky, MD, Endocrinologist, University of Southern California Keck School of Medicine, CA

Lori J. Wirth, MD, Medical Oncologist, Massachusetts General Hospital Cancer Institute, National Institutes of Health, MA

Samuel A. Wells, MD, Surgeon, National Cancer Institute, National Institutes of Health, MD

Mark Zafereo, MD, Head & Neck Surgeon, University of Texas, MD Anderson Cancer Center, TX

In Memory and Gratitude
Ernest L. Mazzaferrri, MD
Jeffrey F. Moley, MD
Yolanda C. Oertel, MD
Arturo R. Rolla, MD
Our Mission

ThyCa is an international nonprofit 501(c)(3) organization of thyroid cancer survivors, family members, and health care professionals, dedicated to education, communication, support, awareness for early detection, and thyroid cancer research fundraising and research grants. Our mission is to educate and support the global thyroid cancer community and invest in research.

Vision: A world free of thyroid cancer.

Since 1995 we have been developing a unique support network to link survivors and healthcare professionals around the world. Volunteers donate their time and effort to make our dreams a reality.

People in 115 countries receive our free services. Our free services and materials are available to everyone whose life has been touched by thyroid cancer.

Our Services

2 Online Support Communities
Linked through the website. These include the ThyCa Inspire Thyroid Cancer Support Community, plus Groups.io discussion community.

Person-To-Person Support
One-to-one support with ThyCa volunteers, matched by thyroid cancer type and situation.

Local Support Groups
Around the United States, Honduras, and in Ireland.

Conferences, Workshops, Seminars
Our Conferences bring thyroid cancer experts, survivors, and families together to learn the latest about thyroid cancer and give and receive support. We also hold many free one day regional workshops and local seminars.

Comprehensive Website
Thyroid cancer information in 11 languages: English, Arabic, Chinese, French, Greek, Hebrew, Italian, Japanese, Portuguese, Russian, Spanish. Dozens of free downloadable publications, videos, plus events calendar, support group connections, Facebook and Twitter connections, and more. All medical information receives review and input from more than 50 thyroid cancer experts, including members of ThyCa’s Medical Advisory Council plus more specialists. ThyCa adheres to the HONCode Principles for health information on the internet.

Research Fundraising & Thyroid Cancer Research Grants
ThyCa has proudly awarded 106 thyroid cancer research grants totaling more than $2.8 million, to researchers in 7 countries.

Survivors’ Toll-Free Telephone Number
(877) 588-7904

Free Tools for Education, Support, & Awareness
For these and more, visit www.thyca.org

Handbooks
Thyroid Cancer Basics
• About all types of thyroid cancer
• Download or by mail
• Free in bulk to healthcare professionals
• In English, Arabic, Chinese, Hebrew, Italian, Russian, and Spanish

Anaplastic Thyroid Cancer
• In English, Chinese, and Spanish

Medullary Thyroid Cancer
• In English, Chinese, and Spanish

Thyroid Nodules: Testing and Follow-Up
• In English and Arabic

Online Monthly Newsletter
Subscribe at www.thyca.org/guestbook

Patient Information Packets by Mail
Request at www.thyca.org/guestbook, or (877) 588-7904

Free Pediatric Sportpacks
With information plus helpful tips for children and teens with thyroid cancer, and their parents

Low-Iodine Cookbook 9th Edition
• Downloadable from www.thyca.org
• In English, French, Portuguese, and Spanish

FNA Booklets
for Patients and Physicians
• Fine Needle Aspiration of the Thyroid: The Guide for Patients (in English and Spanish)
• Fine Needle Aspiration of the Thyroid: A Procedural Guide for the Physician

Guestbook and Free Monthly Newsletter
Use our website’s convenient Guestbook to sign up for our free online newsletters and special announcements, to request a free Patient Information Packet, and to add or update your contact information.

Your organization is invited to partner with ThyCa in Thyroid Cancer Awareness Month (September) and year-round campaigns

Raise awareness with brochures, flyers, and wallet cards
• Free AACE Neck Check Cards
• Free flyers in English and Spanish: “Find It Early,” “Know the Signs,” “Thyroid cancer IS NOT a good cancer,” “About Thyroid Cancer,” and more
• Free Thyroid Cancer Awareness brochures
• Free wallet cards and patient services brochures
The ThyCa Memorial Quilts and Video

The ThyCa memorial quilts and video slide show were created by two longtime ThyCa volunteers.

Through these tributes, we honor and remember our loved ones who have lost their lives to thyroid cancer.

The quilts are the creation of Leah Guljord of Florida. Cheri Lindle of Oklahoma developed the video slide show. Jessica Weese of Washington is now managing the video slide show.

We will show the video at different times during the Conference.

If you would like for your loved one to be remembered in future tributes, please contact Jessica at jweese@thyca.org.
In Loving Memory

We join together in remembering these wonderful men and women who fought thyroid cancer with courage, strength, and grace.

We dedicate this page to them and to all those who have gone before us.

Dana Berger  
John Boatwright  
Steven Bouquet  
Jesikalee Bravo  
Theresa Chin  
Paula Clayron  
Donna De Bernardi  
Sue Evert  
Dorus Edgar “Eddie” Faires  
Laura Fenner  
Ian Gray  
Luciann J. Greco  
Pam Harris  
Carol Janecek  
Jane Johnston  
Janet Mordecai  
Padma Narayanaswamy  
Maurice Newberry  
Adrienne O’Brien  
Aleka Pahinui  
Bobbi Pennington Carr  
Elisa Jeanne Rassen  
Elizabeth Jean Reynolds  
Nympha “Nancy” Rios Arispe  
Rena Roseman  
Charles “Chuck” Schilling  
Randy Schrickel  
Mitch Serpas  
Ralph Kenan Smith III  
Dana Spanger  
William Townsend Stewart  
Theresa Lynn Thomas  
Vanessa Priscilla Tillman  
Mary Ann Vaca-Lambert  
Patrick D. Weaver  
Mary Rose Weckerle  
Natalie’s mammy

“Life has been shared, the joys and the sorrows. This has been as real and strong as anything in life. The love that once was born can never die, for it has become part of us, of our life, woven into the very texture of our being.”

—John Lovejoy Elliott
Kurt E. Alexander, Esq., General Counsel
Kurt has served as ThyCa’s General Counsel since 1997, after his ex-wife was diagnosed with thyroid cancer. He is Board Certified in Civil Trial Law by The Florida Bar and The National Board of Trial Advocacy. He is also AV Preeminent Rated by Martindale-Hubbell, the highest rating possible, and reflecting the confidential assessments of the Bar and the judiciary. He is a member of ABOTA, the American Board of Trial Advocates, at the Advocate level. Kurt currently serves as a member of the Executive Council of The Trial Lawyers Section of The Florida Bar, and he is its Liaison to the Rules of Civil Procedure Committee of The Florida Bar. He has served as Chair of The Florida Bar Grievance Committee for his part of Florida. Mr. Alexander lives in Central Florida, where he has practiced law for over 30 years.

Gary Bloom, Executive Director
Gary manages ThyCa’s programs and services, leads the Conference planning, is liaison to ThyCa’s Medical Advisory Council, and represents ThyCa at meetings and events. He co-founded ThyCa with 16 others and was ThyCa’s Founding Board Chair. He has facilitated the ThyCa Washington, DC, Support Group since 1999. With 3 physicians, he co-edited Thyroid Cancer: A Guide for Patients. Gary was diagnosed with papillary thyroid cancer with tall cells in 1995, received numerous treatments, and has participated in clinical trials. He lives in Olney, Maryland, with his wife, Hilary.

Bridget Corcoran, Treasurer
After being diagnosed at 21 in 2008, Bridget became passionate about helping fellow survivors as well as educating others about thyroid cancer. She has been the co-facilitator of the ThyCa Chicago, Illinois, Support Group since 2011; has represented ThyCa at medical professionals’ meetings; and has led sessions at ThyCa Conferences. When she’s not working as business manager at her family’s electrical construction company, she enjoys cooking, photography, spending time with family and friends, travel, practicing mindfulness meditation, knitting and driving her BMW. She holds a BSBA in management from Roosevelt University in Chicago.

Anita Hubbard, Recording Secretary
Anita is a thyroid cancer survivor, diagnosed on Valentine’s Day in 2013. Through her experience, Anita was inspired to help others through her own nonprofit focused on raising awareness and funds for thyroid cancer research. Anita is a former corporate executive, now focused on strategic business consulting and raising her young family in Texas.

Daria Jerauld
Originally diagnosed in March 1996 (PTC), Daria has had two recurrences. Her first ThyCa conference was Chicago (2004). She facilitated the Waterloo, Iowa support group and now SE Kansas group. She coordinates ThyCa’s Toll-Free Number (TFN). Daria has led roundtables at ThyCa Conferences. She retired from John Deere after 34 years. She’s now ThyCa’s Director of Social Media and volunteers on the Publications team. She helped edit ThyCa’s 9th Edition LID Cookbook. Daria is married to her husband Bob. She has two adult children. Daria enjoys her dogs, travel, cooking and Star Trek. Daria holds degrees in Engineering and Psychology.

Bill McClain
Bill is an author and businessman who lives with his wife in Milford, CT. He consults on Strategic Planning and published the book “Strategic Planning In This Age Of Disruption”. Writing under the pen name William Kenly, he has published three books, including “The Dogs of Cancer: Dancing with Medullary Thyroid Cancer”, and is an editor and contributing author to “After the Diagnosis: Medullary Thyroid Cancer Memoirs”, and the new MTC book, “The Butterfly Sings”. He has co-facilitated past conference roundtables with his wife Galina, and he is also on the Board of Directors of the Cornel Scott Hill Health Center in New Haven, CT. He was diagnosed with sporadic medullary thyroid cancer in 2008.

Bill Nelson
Bill is an attorney, author, and speaker living on the southern tip of Lake Michigan. He earned a B.A. in Business Administration from Taylor University and a Juris Doctorate from Valparaiso University School of Law. He’s been in private law practice for 30 years and serves as a part-time Public Defender. His book, Firm Grip, Learning to Thrive When Life Doesn’t Go as Planned, was published in 2021. He enjoys an active lifestyle that includes fitness and exercise, skiing, cycling, and travel. Bill was diagnosed with medullary thyroid cancer in 2016.

Howard Solomon, Board Chair
Howard is a thyroid cancer survivor and has a lifelong interest in endurance sports, including running and swimming. A graduate of the University of Michigan, he lives in Mill Valley, California with his wife and two children. Howard is Managing Partner for Finn Partners West. Finn Partners is a global group of strategists who develop communications programs across sectors and media platforms.
In Appreciation for your Generous Support of ThyCa

**GOLD SUPPORTERS**
Bayer U.S. L.L.C.
Eisai, Inc.
Exelixis, Inc.
Lilly Oncology

**BRONZE SUPPORTERS**
Blueprint Medicines
Novartis
Takeda Pharmaceuticals America, Inc.

**SUPPORTERS**
Sonic Healthcare
ThyCa’s Members and Individual Donors

---

**WE ARE GRATEFUL TO THESE ORGANIZATIONS FOR THEIR ASSISTANCE**
American Academy of Otolaryngology-Head and Neck Surgeons
American Association of Clinical Endocrinologists
American Association of Endocrine Surgeons
American Head and Neck Society
American Society of Clinical Oncology
American Thyroid Association
*Coping with Cancer* Magazine
*CURE* Magazine
The Endocrine Society
HypoPARAtyroidism Association
National Cancer Institute
National Comprehensive Cancer Network
National Organization for Rare Disorders
Society of Nuclear Medicine and Molecular Imaging

ThyCa’s services and resources are all made possible by the dedicated volunteer efforts of more than 400 individuals and by the generous financial and in-kind donations from individuals and organizations.

These contributions support our free year-round support services, outreach, *Low-Iodine Cookbook*, patient information packets, *Thyroid Cancer Basics*, *Anaplastic Thyroid Cancer*, *Medullary Thyroid Cancer*, and *Thyroid Nodules: Testing and Follow-Up* Handbooks, many more free publications, the webinar series, seminars, workshops, and this conference. The grants from organizations are unrestricted educational grants. Thank you very much to all our donors.

---

**DONORS OF GOODS AND SERVICES**
John Balderston
Benihana
Gary & Hilary Bloom
Rita Bramhall
Bronca
Chipotle
Roxanne Cimo
Anjali & Jim Davis
Carol DiFelice
Colleen & John Dolinish
Merry for a Cause, Amanda Ehrler
Bekka Fehr
The Four Seasons Hotel Baltimore
Marla Friedman
Karen & Bob Giesenberger
Deb Graves
Michaela Hart
Bob & Daria Jerauld
The Jewelry Standard
Jim J Woodworking, Jim Smith
David Kalish
William Kenly
Karen Kline
Christine Kuchta
Mark Luff
Julie Martwick
Abby & Miguel Melendez
P&T Construction LLC
Rack Room Shoes
Sandi & Louis Schlager
Sioux Sciaccia
Six Flags & Hurricane Harbor Maryland
Sprouts Farmers Market
Rick Steves
Suzanne Stipek
Nancy Thompson
ThyCa Cleveland Support Group
ThyCa Colorado Springs Support Group
ThyCa Raleigh, NC Support Group
ThyforLife Health Inc.
Suzann & Barry Tom
Sondra Touris
Patti Turner
Uncle Julio’s Mexican Restaurant
Charlie & Laura Villmer
Theresa & Dan Wickerham
Ellen Yetvin-Haven
Paula & Carl Zielonka
26th International Thyroid Cancer Survivors’ Conference

We hope to be in person in 2023
Location to be announced

www.thyca.org